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Abstract 
Sexual transmission accounts for the majority of HIV infections, with women bearing the brunt 
of the epidemic.  A detailed understanding of early events during HIV transmission and the 
nature of the incoming virus will aid the design of vaccines and microbicides. The aim of this 
dissertation was three-fold:  firstly, to characterize the genetic bottleneck associated with 
transmission in participants with acute infection in the Mbeya region of Tanzania; secondly, to 
investigate the biological features of transmitted/founder (T/F) viruses; and lastly to determine 
how these properties impact on subsequent disease progression. 
The Mbeya region of Tanzania has a genetically complex HIV epidemic with multiple subtypes 
and recombinant forms circulating, together with a high frequency of dual infections with more 
than one subtype.  A total of 212 env sequences from 22 participants were generated from 
recently infected women from Mbeya using the single genome amplification (SGA) approach.  
Participants were infected with subtypes C (n=9), A (n=4), D (n=1); or recombinants AC (n=4), 
CD (n=2), AD (n=1), or ACD (n=1).  In sixteen participants (73%) clinical infection was the 
result of a single variant; whereas in five participants (23%) there was evidence of multiple 
variant infections with more than one closely related quasispecies; and one (4%) participant was 
identified to be dually infected. This individual was believed to be simultaneously infected with 
two phylogenetically distinct viruses prior to seroconversion, as opposed to superinfection, in 
which the second infection occurs after seroconversion.  Thus the frequency of single variant 
infections was similar to cohorts located in genetically restricted subtype B or C epidemics, 
suggesting that multiple circulating subtypes and unique recombinant forms do not have a 
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In order to characterize the Envelope function of T/F viruses, env sequences that matched the 
consensus of SGA - derived sequences sampled in very early infection, were cloned and used to 
generate pseudoviruses.  There was a wide variation in the host cell entry efficiency between the 
T/F Envelope clones, which suggests that the genetic bottleneck does not select for viruses with 
equal ability to infect cells.  The viruses with high entry efficiency had significantly higher viral 
loads at 3 and 12 months post infection (p = 0.0022; p = 0.0347, respectively), suggesting that 
viruses with high entry efficiency at transmission may predict disease outcome. The entry 
efficiency of the Env pseudovirions was measure using dual inducible HEK293 Affinofile cells, 
which were induced to express different levels of CD4 and CCR5. While all viruses could infect 
cells with high CD4 and CCR5, only 30% of the viruses were able to mediate entry efficiency at 
low levels of CD4, suggesting that high levels of CD4 are critical for entry of these viruses.  The 
ability of the pseudoviruses to  enter cells with low CD4 and CCR5 levels was significantly 
associated with the IC50 values for soluble CD4 (p = 0.0438) and CCR5 antagonist, TAK779 (p 
= 0.0138), suggesting that receptor affinity contributed to these differences in entry efficiency.  
The level of Envelope processing/incorporation and fusion capacity was more efficient in viruses 
with high entry efficiency, although this was not consistent for all the Envelope clones.  
Therefore, our study shows that viruses with low entry efficiency and binding affinity to CD4 
and CCR5 can still be transmitted.  However, high levels of entry efficiency seem to provide an 
advantage to the virus, leading to increased viral loads that may enhance disease progression. 
In order to determine the relationship between entry efficiency in vitro and in vivo replicative 
capacity between the T/F viruses, recombinant viruses were generated using the transmitted 
Envelope clones derived from ten participants.  This involved shuttling the Envelope clones into 
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recombinant viruses was measured in TZM-bl cells, PBMCs, and monocyte-derived 
macrophages.  There was variability in replication capacity of the recombinant viruses in 
different donors.  However, the recombinant viruses replicated much more efficiently in CD4
+
 T 
lymphocytes than in monocyte-derived macrophages.  This suggests that macrophages may not 
be the ideal target cells used by T/F viruses during transmission.  The preferential replication in 
T-cells and not macrophages was observed irrespective of the infecting subtype or recombinant 
form.  Although the pseudovirion assays showed an association between high in vitro entry 
efficiency and high viral loads in vivo, we could not confirm this finding in PBMCs due to host 
to host variation.  However, the PBMC assay did support the findings in the 293Affinofile 
pseudovirion assay that transmitted viruses do not infect macrophages, which have low CD4 
expression levels, very efficiently.  
Overall, this study shows that the presence of multiple subtypes and recombinants in a region 
does not affect the transmission genetic bottleneck.  Also, the ability of the viruses to mediate 
host cell entry effectively during transmission is dependent on both viral and host factors.  Viral 
factors such as CD4 and CCR5 binding affinity and, to some extent, Envelope 
incorporation/processing and cell-cell fusion capacity; and host factors such CD4 and CCR5 
expression levels can impact entry efficiency; and collectively these properties could influence 
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bp                                Base pairs 
B-gal                            Beta-galactosidase 
ºC                                 Degrees Celsius 
C1-C5                          Conserved regions 1-5 
CCR5                           Chemokine coreceptor 
cDNA                          Copy DNA 
CI                                Confidence Interval 
CMV                           Cytomegalovirus 
CRF                             Circular Recombinant Form 
CO2                              Carbon dioxide 
CTL                             Cytotoxic T Lymphocytes 
CXCR4                         CXC chemokine coreceptor       
DC-SIGN                     Dendritic Cell-Specific Intracellular adhesion molecule-3-Grabbing Non-Intergrin   
DNA                            Deoxyribose nucleic acid 
E.coli                           Escherichia coli 
EDTA                          Ethylenediaminetetraacetic acid 
ELISA                          Enzyme-linked Immunodeficiency Assay 
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HIV                                Human Immunodeficiency Virus 
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mRNA                             Messenger Ribonucleic  acid 
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Human Immunodeficiency Virus (HIV), the causative agent of Acquired Immunodeficiency 
Syndrome (AIDS), has had a devastating effect worldwide with an estimated 34 million people 
infected (UNAIDS, 2012).  High levels of HIV diversity remains one of the major obstacles in 
the development of an efficacious vaccine.  An understanding of the extent of viral genotypic 
and phenotypic diversity in different geographical regions will help in designing a globally 
efficacious vaccine.  Following transmission, the virus is initially contained locally in the 
mucosa for a few days before susbsequent systemic infection (Li et al., 2009a), and the limited 
inoculum following transmission and low diversity during early infection provides a ‘window of 
opportunity’ for vaccines to act.  Thus a major focus in the field is to understand the 
characteristics of the incoming transmitted or founder viruses that establish infection, as these are 
the precise targets of vaccines and microbicides.  The aim of this dissertation is three-fold:  
firstly, to characterize the extent of the diversity of the transmitted/founder virus population 
during acute infection in the Mbeya region of Tanzania; secondly, to investigate the biological 
features of transmitted viruses; and lastly to determine how these properties impact on 
subsequent disease progression. 
This study forms part of the Mbeya Medical Research Programme, and was conducted using 
plasma samples from recently infected women from the Mbeya region of Tanzania, which is a 
region that has number of subtypes co-circulating.  This cohort comprised of 600 HIV positive 
and HIV negative female bar workers who were at high risk of infection, and were followed up 
every three months over 3 years as part of HIV Superinfection Study (HISIS) cohort (Hoelscher 
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This literature review will provide an overview of the extent of HIV-1 diversity both within 
Tanzania and rest of the world, the current thinking in this field with regard to the early events 
following transmission, and what is known about the characteristics of the incoming 
transmitted/founder virus population.  This will give a broader understanding of both host and 
viral factors that affect transmission. 
 
1.1 HIV diversity 
 
HIV is classified into two genetically distinct types, type 1 (HIV-1) and type 2 (HIV-2) which 
are then further subdivided into a hierarchy of groups and subtypes based on genetic variation.  
This thesis focuses only on HIV-1, which is classified into four Groups (M, major; O, outlier; N, 
non-M, non- O; and P) and Group M further divided into 9 subtypes (A1, A2, B, C, D, F1, G, H, 
J, and K) (Robertson et al., 2000); HIV Sequence Database. http://www.hiv.lanl.gov) (Fig. 1.1).  
In regions of the world where various HIV subtypes co-mingle, recombinant viruses have 
emerged resulting in the formation of circulating recombinant forms (CRFs), complex CRFs 
(CRFcpx), and unique recombinant strains (URFs).Circulating recombinant forms are 
intersubtype recombinant viruses that are transmitted to many people and as a result become one 
of the circulating strains in the HIV epidemic. For example, the CRFO7_BC consists of regions 
of both subtypes B and C. Unique recombinant viruses are recombinant viruses with unique 
breakpoints and have limited transmission in the human population. These URFs are usually 
produced in a dually infected or multiply infected individual (Robertson et al., 2000; Los 
Alamos, 2007). If the recombinant infects many people and becomes a circulating strain in an 
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individuals that are not epidemiologically related, and therefore can be assumed to have to have a 
significant contribution on the HIV epidemic. When these viruses are created, they circulate in 
regions independent of their parental subtype.  Currently, there are 48 CRFs that have been 
identified (see Los Alamos National Lab (LANL)-database; http://www.hiv.lanl.gov). 
       
Figure 1.1. Classification of HIV into HIV-1 and HIV-2 with the former divided into 4 groups with the Group 
M comprising of 9 subtypes, 48 circulating recombinant forms (CRFs), and unique recombinant forms 
(URFs) (modified from www.avert.org).   
 
1.2 Worldwide distribution of HIV subtypes and circular recombinant forms 
 
HIV originated in equatorial central Africa, and diversity in this region can be attributed to viral 
evolution (Corbet et al., 2000; Gao et al., 1999; Keele et al., 2006; Santiago et al., 2002).  
However outside of this region, the global distribution of subtypes and CRFs largely reflects the 
historical spread of the virus.  There is an uneven distribution of HIV subtypes and circulating 
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in certain geographic regions.  This uneven distribution can be largely attributed to founder 
effects, although differences in biological properties of the virus may also play a role (see 1.9.2).      
 
Founder effects result when a single virus is introduced into a transmission network, resulting in 
the spread of that subtype in the region (Rambaut et al., 2004).   There are numerous examples of 
founder effects:  the Subtype C epidemics in India, Ethiopia and South America  (Fontella et al., 
2008); the subtype B epidemic in Haiti and North America (Gilbert et al., 2007) and CRF strains 
CRF01_AE and CRF02_AG in Thailand and West/ Central Africa, respectively (McCutchan et 
al., 1992; Montavon et al., 2000).   
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1.3 Mechanisms of HIV diversification 
 
HIV evolves more rapidly than other known organism (Rambaut et al.,  2004) enabling the virus 
to rapidly adapt to the host, and avoid detection by the host’s immune system.  Mechanisms of 
HIV diversification include recombination and a high mutation rate due to the error-prone 
reverse transcriptase enzyme.  The error-prone nature of reverse transcriptase causes a mutation 
rate of 0.3 nucleotide changes per genome per replication cycle, resulting in the emergence of a 
cloud of highly related but distinct viruses (quasispecies) within an infected individual  (Mansky, 
1995).  Recombination occurs when the reverse transcriptase switches RNA templates during 
replication, thereby forming progeny viruses that are representative of different parent viruses 
(Wooley et al., 1997) .  HIV has one of the highest recombination rates compared to other 
organisms, with approximately 2.8 recombination events occurring per genome per replication 
cycle  (Zhuang et al., 2002).  The recombination rate, therefore, exceeds the mutation rate per 
replication cycle.  Recombination events can occur between viruses from different subtypes 
(intersubype recombination) and also viruses derived from the same subtype (intrasubtype 
recombination) (Takehisa et al., 1999).  
HIV sequence evolution is also affected by the host innate restriction factor, such as APOBEC3, 
which blocks retroviral infection.  The two main cellular proteins APOBEC3F and APOBEC3G 
deaminate deoxycytidine to deoxyuridine on the first retroviral DNA strand (minus strand) 
during reverse transcription of RNA into cDNA.  If APOBEC is incorporated into the virion, it 
will result in the deamination of cytosine and also the accumulation of uracil residues, resulting 
in guanosine-to-adenosine (G-to-A) hypermutations which are detrimental to the viral replication 
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factor (Vif) protein which acts by binding to the APOBEC and targets it for proteosomal 
degradation  (Sheehy et al., 2002; Yu et al., 2003).  There have been conflicting reports on the 
effect of hypermutation on disease progression. A study by Pace et al., (2006) found a reduction 
in viral load in individuals with detectable hypermutation in the peripheral blood mononuclear 
cells, and (Land et al., 2008) found an increase in the amount of CD4 cells when hypermutation 
of HIV was detected.  Conversely, others studies have not found any correlation between 
hypermutation and viral load (Piantadosi et al., 2009a; Ulenga et al., 2008). A study by Wood et 
al., (2009) found that transmitted/ founder viral sequences in recently infected participants with 
subtype B contain rapidly evolving sites that are embedded in an APOBEC motif and in a CTL 
epitope, suggesting that APOBEC -  induced mutations may facilitate viral escape.  
 
1.4 HIV diversity and subtype distribution in Tanzania  
 
This thesis characterized viruses from high risk women from the Mbeya region of Tanzania.  The 
number of people that are infected with HIV in Tanzania is estimated to be at 1.5 million 
(UNAIDS report, 2012).  HIV subtypes A, C, and D were identified as predominant subtypes 
since the early 1990s (Hoelscher et al., 1998), and the distribution of the subtypes varies 
depending on the geographic region sampled. HIV subtype A and D were the predominant 
subtypes in the northern parts of Tanzania, with subtypes A, C, D co-circulating in the 
Kilimanjaro region (Nyombi et al., 2008), together with a number of intersubtype recombinants 










Chapter 1: Introduction and Literature Review 
   8 
 
The HIV-1 prevalence in adults of 8 % in Mbeya is higher than in the rest of the country 
(UNAIDS report, 2010), with the epidemic driven by genetically complex viruses, with subtype 
C identified as the predominant subtype in the southwestern region of Mbeya.  Using the multi-
region hybridization assay, the subtype distribution in this region was found to be subtype A (8.5 
%), subtype C (40.8 %), D (3.8 %), along with a number of recombinants AC (25.4 %), AD (5.4 
%), CD (8.8 %), and ACD (7.3 %) (Arroyo et al., 2005; Herbinger et al., 2006). 
Full-length sequencing and recombination analysis identified the intersubtype recombinants as 
unique, as they did not share recombination breakpoints with any previously identified 
recombinant strains (Hoelscher et al., 2001).  In this region, there was a higher frequency of 
recombinant strains (54 % vs 40 %) and infection with more than one subtype (dual infections) 
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1.5 Dual infection 
 
Dual infection occurs when an individual is infected with two phylogenetically distinct and 
epidemiologically unlinked viruses, which ultimately results in the generation of recombinant 
viruses.  These viruses can either be derived from the same subtype (intrasubtype) or from 
different subtypes (intersubype).  Dual infections can occur either by coinfection or by 
superinfection. Coinfection is defined as infection with two strains, either simultaneously or 
within rapid succession of one another prior to seroconversion.  Superinfection occurs when an 
HIV infected individual becomes infected with a second strain after an immune response to the 
initial strain has been established  (Gottlieb et al., 2004; Grobler et al., 2004; Smith et al., 2005; 
Zhu et al., 1995).  Dual infection has been shown to affect disease progression with an 
association identified between dual infection and high viral load set point (Grobler et al., 2004) 
as well as rapid disease progression where individuals who were dually infected with two HIV 
subtype B viruses, and progressed to AIDS within 1.5 years of seroconversion, compared to 
single infected individuals who progress to AIDS within 8-10 years (Gottlieb et al., 2004). 
However, a recent study by Woodman et al., (2011) did not find an association between dual 
infection and disease progression.  It has been suggested that dual infection, which is common in 
the Mbeya region of Tanzania, will enable rapid recombination which might allow viruses to 
adapt faster and exploit cellular niches more efficiently than single infections with low diversity 
(Gottlieb et al., 2004; Herbinger et al., 2006). 
Recent studies have investigated factors that make individuals susceptible to superinfection. It 
has been shown that superinfected individuals mount a low autologous neutralizing antibody 
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et al., 2012; Smith et al., 2006).  Following superinfection however the neutralizing antibody 
response appears to broaden as a result of antigenic stimulation by a second distinct virus (Cortez 
et al., 2012).   Although individuals that are superinfected with  discordant HIV subtypes have an 
effective neutralizing antibody response against heterologous viruses, their potency against 
autologous viruses is not different compared to singly infected individuals (Mayr et al., 2012).  
The role of HIV-1 CTL specific immune response in providing protection to superinfection is not 
clear. The HIV-1 CTL immune response, both in human and primate studies, does not seem to be 
effective in providing protection to superinfection, and it is likely that protection from 
superinfection requires a much higher frequency of T cells with a different specificity than those 
present during chronic infection (Blish et al., 2012; Weinfurter et al., 2011).  
 
1.6 Immune responses impacting on viral genotype and phenotype following infection.   
 
1.6.1 Cell-mediated immunity to HIV-1 infection 
 
Cytotoxic T-lymphocytes (CTLs) play an important role in suppressing viral replication, both 
during acute and chronic infection.  After infection, the viral peptides become processed inside 
the endoplasmic reticulum, before being transported to the cell membrane for presentation by the 
Major Histocompatibility Complex (MHC) class I molecules.  The presentation of the viral 
peptide on the surface of the cell triggers a response by the CTLs. The T cell receptors (TCR) 
that are expressed on the surface of CTLs bind to the MHC class I molecules and its peptide on 
the surface of the virus-infected cells, and induces the release of perforins and proteases that lyse 
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mutational mechanisms to avoid recognition by CTLs. Mutational escape mechanisms are amino 
acid changes in the viral peptides or epitopes that reduce binding to the MHC class I molecules 
and/or alter the interaction with the TCR.   These changes result in a loss of recognition by CTLs 
(Le Gall et al., 2007; Goulder et al., 2004;  Klenerman et al., 1994; Tenzer et al., 2009).   
Another possible mutational escape by HIV-1 involves interfering with the intracellular 
processing of the viral peptides, which prevents these epitopes from being presented at the cell 
surface in the context of MHC class I molecules for recognition by CTLs.  
The escape of CTLs by HIV is also achieved by nonmutational mechanisms such as the 
downregulation of the MHC class I molecules by the HIV infected cells (McMichael, 1998).  
This function is mediated by the Nef protein of HIV, which causes the MHC class 1 molecules to 
accumulate in clathrin coated vesicles in the Golgi apparatus resulting in the lack of recognition 
of the infected cell by the CTLs (Tomiyama et al., 2002).  
There has been overwhelming evidence over the years that support the role of human leukocyte 
antigen (HLA) molecules, and by implication CTLs, in determining the rate at which individuals 
progress to disease after infection (Fellay et al., 2007).  A genome wide association study 
identified single nucleotide polymorphisms (SNPs) in HLA region of chromosome 6 associated 
with viral control.  Further analysis in the HLA B gene found five amino acids that are critical 
for the binding of the viral peptide to the HLA binding groove. There was also a single 
polymorphism that was found in the HLA- C gene, which is 35kb away from the transcription 
initiation site.  This allele has been involved in the high expression of the HLA-C gene, which 
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The HLA molecules determine how different individuals can respond to specific 
immunodominant epitopes and certain CTL response are more effective at controlling viral 
replication than others.  HLA alleles such as HLA B*27, HLA B*57, HLA B*58, and HLA 
B*63 have been strongly associated with immune control of HIV, resulting in slower disease 
progression (Gao et al., 2001; Kaslow et al., 1996 Kiepiela et al., 2004; Migueles et al., 2000). 
On the other hand, individuals with HLA alleles such HIV B*35 and HLA B*53 has been 
associated with rapid disease progression (Carrington & O’Brien, 2003; Carrington, 1999; Itescu 
et al., 1992).   
CTL have been shown to play a role in suppressing viral replication during acute infection until 
the viral set point is achieved, and responses during acute infection appears to be very narrow 
(Borrow et al., 2007).  CTL infection occurs as early as two to three weeks after infection 
(Goonetilleke et al., 2009a; Lichterfeld et al., 2004; Mlotshwa et al., 2010), and Nef, Gag, and 
Pol are regions that are mostly targeted during the first 6 months of infection (Goonetilleke et al., 
2009b; Gray et al., 2009a; Mlotshwa et al., 2010).  During chronic infection, the Gag and 
Envelope-specific CTL response have been found to be associated with low and high viral loads 
respectively, suggesting that Gag, and not Envelope, is critical in CTL-mediated viral control 
(Geldmacher et al., 2007; Kiepiela et al., 2007).  Also, the most protective HLA alleles such as 
HLA B14, B27, B57, B58, B81 target very conserved regions in Gag, resulting in lower viral 
loads.                    
1.6.2 Humoral immunity to HIV-1 infection 
 
The first antibody response produced by the B cells are in the form of virion - antibody immune 
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usually emerge 2 to 3 weeks post-infection (Tomaras et al., 2008).  The anti-gp41 antibodies are 
followed by the anti-gp120 antibodies a few weeks later, and these antibodies target the V3 loop. 
These antibodies do not have an effect on viremia (Tomaras et al., 2008).  Antibodies that are 
able to prevent infection are called neutralizing antibodies and these usually appear a few months 
post-infection (Gray et al., 2007; Li et al., 2006; Wei et al., 2003) (Fig. 1.4).  These early 
antibodies are effective against the autologous virus but are usually unable to neutralize 
divergent viruses from other hosts (Moore et al., 1994).  The plasticity of the HIV genome, and 
the narrow specificity of the antibody response, allow the virus to easily escape these responses 
(Moore et al., 2009; Rong et al., 2009; Wei et al., 2003).  Viruses are able to evade antibody 
responses through disruption of epitopes by means of single amino acid substitutions, insertions 
and deletions, as well as by structural shielding which can occur through shifting N-
glycosylation sites that prevent access of the antibodies to the viral epitopes or by elongation of 
variable envelope domains (Bunnik et al., 2008; Herrera et al., 2003; Overbaugh & Rudensey, 
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Figure 1.4. The timing of CTL and antibody responses during acute stage of HIV infection (Cohen et al.,  
2011).  The laboratory staging indicated in Roman numerals with the detection of viral RNA, and viral antigens 
indicated  (Fiebig et al., 2003). Individuals classified as being in Stage I/II were viral RNA positive, ELISA 
antibody negative; those in stage III were ELISA antibody positive but negative by Western blot; those in stage IV 
had an indeterminate Western blot; those in stage V were Western blot positive but without reactivity to the p31 
integrase band; and those in stage VI were Western blot positive with a p31 band present.    
 
Autologous neutralizing antibodies preferentially target certain regions in the viral envelope 
protein, particularly the V1V2 region because it is on the outer surface of the virus and is also 
extensively N-glycosylated (Overbaugh et al., 1991).  V1V2 length was correlated with the 
levels of N-linked glycosylation, with both mechanisms thought to be important for the viral 
evasion of the humoral immune response (Curlin et al., 2010).  The C3-V4 region has also been 
shown to be a target for neutralization during early subtype C infection (Moore et al., 2008).   
This target is more common in subtype C due to the variability of the alpha-2 helix in the C3 
region and a shorter V4 region in subtype C viruses compared to subtype B viruses (Gnanakaran 
et al., 2007).  V3-V5 region, and the V1V2 region in association with the gp41 region or V3 loop 
have also been implicated as targets for neutralizing antibodies  (Rong et al., 2009; Tang et al., 
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Antibodies that are able to neutralize a range of viruses are called broadly neutralizing 
antibodies, and these have been identified in approximately 10 – 30 % of individuals after three 
years of infection (Doria-Rose et al., 2009; Gray et al., 2011a; Sather et al., 2009; Simek et al., 
2009).  It is still unclear why certain individuals develop these antibodies and others do not. It 
has been shown that longer periods of infection and high levels of viremia (causing persistent 
viral stimulation) are associated with the development of neutralization breadth (Euler et al., 
2010; Gray et al., 2011b; Piantadosi et al., 2009b; Sather et al., 2009).  Several studies have 
reported that infection with a subtype A and C viruses results in greater breadth and potency than 
subtype B viruses (Brown et al., 2008; Bures et al., 2002; Dreja et al., 2010; Li et al., 2006).  A 
number of cross-reactive monoclonal neutralizing antibodies, and the epitopes that they target, 
have been identified.  These include the IgGb12 (CD4 binding site target), 4E10 (carboxy 
terminal MPER target), 2F5 (amino-terminal MPER target), 2G12 (high mannose region of 
gp120), and the more recently discovered PG9 and PG16 (V1/V2 target), VRC01 (CD4 target), 
and PGT 127 and 128 antibodies (gp120 V3 loop) (Binley, 2009; Gray et al., 2009a, b; Li et al., 
2009a; Pejchal et al., 2011).   
 
1.7 Structure and function of HIV Envelope (Env)  
 
The HIV Envelope is the target of neutralizing antibodies, mediates viral tropism, and is a major 
determinant of viral fitness (Marozsan et al., 2005).  The HIV Envelope is a heterodimer 
comprised of gp120, which is involved in the attachment of the virus to the target host cell, and 
gp41, which is involved in the fusion between the viral and host membrane resulting in the entry 
of the viral material inside the host cell.  These dimers are structurally organized as trimers 
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Envelope protein is initially synthesized as a 160 KDa single polyprotein precursor in the 
endoplasmic reticulum (Freed & Martin, 1995; Wyatt, 1998).  The protein subsequently 
undergoes several post-translational modifications, which include the addition of N-linked high 
mannose oligosaccharides resulting in an extensively glycosylated protein (Bernstein et al., 
1994; Leonard et al., 1990). This process is essential for protein folding and conformational 
stability of the protein.  The glycan sugars on the protein become trimmed and modified by 
cellular enzymes as it is transported through the Golgi network (Fenouillet et al.,  1994; Wyatt, 
1998).  Within the trans-Golgi network, the 160 kDa becomes cleaved by the cellular enzyme 
furin into gp120 and gp41 at a K/R-X-K/R-R motif (Freed et al., 1989; McCune et al., 1988).  
The cleavage is critical for fusion efficiency and also the infectivity of the virus. The three 
molecules of gp120 and gp41 combine to form a heterotrimer Envelope spike, and the two 
subunits are joined by noncovalent interactions (Egan et al., 1996; Rowell et al., 1995).  The 
Envelope is transported to the plasma membrane and can be recycled by endocytosis.  As the 
viral budding occurs, the gp120-gp41 is incorporated in the virus and thereafter is displayed as 
viral spikes on the surface of the virion (Wyatt, 1998).  The gp120 and gp41 subunits form a 
cage-like structure which has a void surrounding its axis, and this architecture could be important 
in restricting antibody access to the virus (Mao et al., 2012).  
 
The gp120 component consists of five conserved (C1- C5) and five variable (V1- V5) regions 
(Modrow et al., 1987).  The conserved regions are important in the interaction with gp41.  These 
regions are accessible to antibodies that bind to monomeric gp120, but not to gp120-gp41 
complexes (Helseth et al., 1991; Moore et al., 1994; Olshevsky et al., 1990).  The C2, C3, and 
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(Moore et al., 1994).  The conserved regions is critical to CD4 binding (Olshevsky et al., 1990), 
and certain mutations in the C2 and C3 region affect the binding of gp120 to CD4 (Douagi et al., 
2010; Wyatt, 1998).  The conserved region C1 is involved in the processing of the furin 
recognition site which is found in the C5 region, and also important in the interaction between 
gp120 and gp41 (Wang et al., 2008).  
In comparison to the conserved regions, the variable regions (mainly the V1, V2, V4, and V5 
regions) are much more exposed and extensively glycosylated (Kwong et al., 1998; Kwong et 
al., 2000; White et al., 2010) thereby shielding the conserved regions from being recognized by 
the antibodies.  Deletion of V1, V2, and V3 regions does not affect binding to the CD4 and, 
suggesting the variable regions are not important in CD4 binding (Cao et al., 1997; Checkley et 
al., 2011; Moore et al., 1994; Wyatt et al., 1993, 1995).  However,  the V3 region has been 
shown to be important for membrane fusion (Freed et al., 1991) and viral tropism (Cilliers et al., 
2005; Shioda et al., 1991).  A switch from CCR5 to CXCR4 is associated with an increase in the 
positive charge of the V3 region, thus allowing for an interaction with the negatively charged 
CXCR4 coreceptor (Pollakis et al., 2004).  Mutations in the crown and the base of the V3 region, 
along with the bridging sheet of the gp120 region also affect co-receptor binding (Cormier & 
Dragic, 2002; Cormier et al., 2001). The role of the V3 region in coreceptor binding will be 
discussed in more detail later in the review (see section 1.7.1).  The role of V4 and V5 is less 
well described, however it is known that the deletion of V4 affects Envelope conformation and 
glycan packing (Frost et al., 2005b; Teeraputon et al., 2005; Wei et al., 2003), thus potentially 
limiting neutralizing antibody access.  
The gp41 region is approximately 345 amino acids in length, and consists of three domains: the 
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extracellular domain consists of the fusion peptide (which is the N-terminal hydrophobic region) 
(Freed & Martin, 1995; Freed et al., 1990), the polar region which consists of two heptad repeats 
HR1 and HR2 (Chan et al., 1997;Weissenhorn et al., 1997), and the membrane proximal external 
region (MPER) (Muñoz-Barroso et al., 1999).  The transmembrane domain has a 25 amino acid 
highly conserved region that allow the envelope protein to anchor into the lipid bilayer.  
Mutations in this region has been shown to affect fusion, suggesting that this region plays an 
important role in Envelope function (Kondo et al., 2010; Shang & Hunter, 2010; Shang et al., 
2008; Zeller et al., 2001).  The C-terminal cytoplasmic tail consists of three helical segments that 
are known as lentiviral lytic peptides (LLP1, LLP2, and LLP3) (Lee et al., 2002).  These 
peptides have been previously shown to play a role in fusogenicity (Kalia et al., 2003), protein 
stability (Lee et al., 2002) , multimerization (Lee et al., 2000), and cell surface expression and 
incorporation (Piller et al., 2000).  
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1.7.1 The role of HIV Envelope in host cell binding and entry 
 
The functional Envelope trimer is involved in the binding of viral gp120 to the host cell CD4 
receptor and coreceptor molecules, which ultimately results in the entry of the virus into the host 
cell (Berger et al., 1999; Wyatt, 1998).  This thesis aims to measure differences in Envelope 
entry efficiency between transmitted viruses, and how this impact on their overall replication 
capacity.  An understanding of the mechanism and the efficiency at which the transmitted viruses 
mediate host cell entry can help in the design of novel compounds to prevent infection.  
The process of host cell entry by HIV-1 involves the binding of the trimeric Envelope protein to 
CD4 and a chemokine coreceptor, which is usually either CCR5 or CXCR4 (Berger et al., 1999).  
The essential role of the CCR5 coreceptor during entry was observed when individuals who were 
homozygous for a 32bp deletion in the CCR5 gene (Δ 32- CCR5) were largely protected against 
HIV-1 infection, and those that were heterozygous for the Δ 32- CCR5 allele showed delayed 
disease progression (Liu et al., 1996).  It has been well documented that viruses that utilize the 
CCR5 coreceptors, termed R5 viruses, are predominately found early during infection, while 
viruses that utilize the CXCR4 coreceptor, termed X4 viruses, are detected later during infection, 
and are associated with rapid CD4 decline and disease progression (Connor et al., 1997; 
Schuitemaker et al., 1992).  R5 viruses predominate early during infection for all modes of 
transmission  (Masharsky et al., 2010). 
Prior to CD4 binding, the first step to host cell entry is the adhesion of the virus to the host cell. 
This event can be facilitated by either the Envelope or membrane proteins that are incorporated 
into the virion with a number of cell attachment factors.  The Envelope protein has been found to 
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proteoglycans (Saphire et al., 2001), α4β7 intergrin (Arthos et al., 2008; Cicala et al., 2011), and 
dendritic cell specific intracellular adhesion molecule – 3 – grabbing non-intergrin (DC-SIGN) 
(Geijtenbeek et al., 2000).  
The entry process involves three important steps which are required in order for infection to 
occur, and these are CD4 binding, coreceptor binding, and membrane fusion.  The first step, 
which is the binding of gp120 to the CD4 receptor, causes the rearrangement of the V1V2, and 
V3 regions, and exposes the conserved regions, which include the gp120 chemokine receptor 
binding site and the gp41 coiled coil domain (Kwong et al., 1998; Zhou et al., 2007).  The 
interaction between gp120 and CD4 results in the formation of the bridging sheet, and the 
repositioning of the V3 region facilitates the binding to the coreceptor (Chen et al., 2005; Kwong 
et al., 1998). The CD4 receptor binds between both the inner and outer domain of gp120. This 
binding creates a highly protected and conserved ‘cavity’, which is also not glycosylated. A 
phenylalanine residue at position 43 (Phe-43) in CD4 has been found to be critical in binding to 
this cavity (Madani et al., 2004; Kwong et al., 2008).  After CD4 binding, the conserved region 
of gp120 gets transformed  from being in a rigid state to being in a flexible state, which allows 
for the interaction with the coreceptor (Kwong et al., 1998). The second step involved the 
subsequent binding to the coreceptors. The gp120-coreceptor interaction triggers the membrane 
fusion capacity of the virus by inducing conformational changes in the transmembrane protein, 
gp41, which exposes the fusion peptide and its penetration into the cell membrane resulting in 
the formation of the fusion pore (Brasseur et al.,  1988). The mapping of the gp120-coreceptor 
interaction suggests that for R5 viruses the N-terminus of the second extracellular loop (ECL2) 
of gp120 are important for coreceptor binding (Wu et al., 1997; Dragic et al., 1998), while the 
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binding steps, additional conformations occur which result in a shift by the viral Envelope from a 
non-fusogenic to a fusogenic state. The N- terminus of gp41 becomes exposed and gets inserted 
in the cell membrane through the fusion peptide. Structural changes within gp41 results in the 
formation of the six-helix bundle strucutre, which is essential for the fusion of the host and viral 
membranes. The change in free energy resulting from the six helix bundle formation provides the 
force needed for the formation of the fusion pore, and the viral genetic material enters the target 
cell through this process (Weiss et al., 2003; Poveda et al., 2005) (Doms and Moore, 2000; 




Figure 1.6. Structure of the Envelope trimer showing the epitopes that are recognized by broadly neutralizing 
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As viral entry is dependent on Envelope binding to host cell surface receptors, the binding 
affinity of gp120 to CD4 and CCR5 as well as the capacity of gp41 to mediate membrane fusion 
influences how the virus will replicate in an environment, which is defined as viral replicative  
fitness.  Natural mutations in the V3 loop region (sites 318 and 319) that decrease the binding 
affinity for receptor/coreceptor molecules (Maroszan et al., 2005; Lobritz et al., 2007), affect the 
sensitivity of HIV to entry inhibitors and the efficiency of host cell entry.   
The specificity of binding to either CCR5 or CXCR4 is determined by the third variable (V3) 
region of gp120 (Fouchier et al., 1992). Recent structural data has shed some light on how the 
interaction between gp120 with CD4 and CXCR4.  The base of the V3 loop binds to the amino-
terminal region of the coreceptor, while the tip of the V3 region binds to the extracellular loop 
(ECL2) of the coreceptor.  A threshold number of CD4 molecules is required for successful 
membrane fusion however the number is not known (Wu et al., 2010).  Cryo-electron 
microscopy, together with antibodies and other reagents that block viral entry, has been used to 
study various conformational changes of the trimeric Envelope at different stages of the viral 
entry process (Harris et al., 2011; Liu et al., 2008; White et al., 2010, 2011).   It has been shown 
that the binding of antibody 17b to gp120, which mimics the binding mechanism of CD4 
receptor, causes the activation of the envelope spike; however CD4 neutralizing antibodies 
VRC01, VRC02, and VRC03 block this activation, thus keeping the envelope in a closed, native 
state.  Therefore, the conformation of Envelope in a 17b-bound sate has revealed an activated 
intermediate state during the entry process which could be useful for the design of novel 
immunogens (Tran et al., 2012). 
A number of studies have been done to determine regions or sites in the env gene that are critical 
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measure the affinity of the virus to CD4 and CCR5 receptors and also fusion capacity.  A study 
by Reeves et al., (2003)  found that mutations that reduced CCR5 binding also resulted in 
increased sensitivity to CCR5 antagonist TAK779. Other regions in the Envelope protein such as 
the C4 region have also been found to be involved in the interaction between gp120 and the 
CCR5 coreceptor (Rizzuto & Sodroski, 2000).  In order to identify viral determinants of 
membrane fusion, Derdeyn and colleagues (2000) identified a tripeptide sequence within HR1 
(GIV at position 36 to 38) that influenced HIV sensitivity to the fusion inhibitor T-20, suggesting 
that this region might be an important interaction site for fusion.  The study also demonstrated 
that the sensitivity of the virus to T-20 is modulated by the specificity in which gp120 interacts 
with the coreceptors.   Mutations in the V3 region and the bridging sheet that reduce  reduced the 
binding affinity of gp120 for CCR5 were found to increase the sensitivity of the virus to T-20 
inhibition (Reeves et al., 2002). 
 
1.7.2 The role of DC-SIGN in cell-cell transfer 
 
Dendritic cells are antigen presenting cells which are present in the mucosa and are one of the 
target cells that encounter the incoming virus during HIV transmission.  The cells engulf the 
incoming antigen, migrate to the lymph nodes where they process and present the virus to T 
cells.  Dendritic cells do not get productively infected by HIV, and this is partly due to their low 
CD4 and coreceptor expression levels, host restriction factors, and many other factors that block 
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Dendiritic cells uses the C-type lectin DC-SIGN to attach to the gp120 region of the virus 
(McDonald et al., 2003).  The virus gets internalized by endocytosis (Geijtenbeek et al., 2000) 
and migrates to the lymph nodes to form a virological synapse with the T cells (Felts et al., 
2010). The formation of these synapes, which is facilitated by attachment proteins like ICAM 
and LFA1 with gp120-CD4 interactions,  facilitates the recruitment of CD4, CCR5, CXCR4, and 
CD4
+
 T cells, resulting in productive infection in the T cells (Hübner et al., 2009; McDonald et 
al., 2003).  
 
1.7.3 The role of intergrins during HIV infection 
 
A group of investigators have identified the role of the homing receptor α4β7 during HIV 
infection.  High levels of the α4β7 receptor, along with CD4 and CCR5, are expressed on the 
surface of mucosal CD4
+
 T cells (Arthos et al., 2008).  When it is expressed, the α4β7 receptor is 
important in the migration of T cells from the gut (mainly the Peyer’s patches and the messentric 
lymph nodes) to the lamina propia (von Adrian, UH; Mackay, 2000; Wagner et al., 1996). 
However, the role of the α4β7 homing receptor in the vaginal mucosa is not yet fully understood.  
These gut-associated lymphoid tissues (GALT) play an important role during early stages of 
infection after sexual transmission.  The high expression levels of CD4, CCR5, and α4β7 make 
them susceptible to HIV infection and may also favour the transmission of R5 viruses (Cicala et 
al., 2011).  The massive depletion of this cell population during the early stages of mucosal 
sexual transmission further highlights the role of these cells as one of the main target cells during 
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These investigators hypothesized that HIV interacts with these cells through gp120 binding to 
the α4β7 receptor (Zeller et al., 2001).  The gp120 binding is mediated by a conserved LDV 
tripeptide in the V1V2 region of gp120 (Zeller et al., 2001).  This region has been previously 
found to be involved in transmission efficiency (Sagar et al., 2006; Wu et al., 2006), highlighting 
the possible role that gp120-α4β7 interactions could play in transmission.  Binding of α4β7 to 
gp120 mimics the binding of MadCAM, VCAM, and fibronectin, which are natural ligands of 
α4β7.  The α4β7 receptor is three times the size of the CD4 receptor, allowing easy viral capture.  
The interaction between α4β7 and gp120 also results in the activation of LFA-1, which is an 
adhesion-associated intergrin.  The LFA-1 intergrin facilitates the formation of virological 
synapses and allows HIV to spread from one cell to another, and also influence in vitro host cell 
entry efficiency (Arthos et al., 2009; Cicala et al., 2009).  As cell-to-cell spread of HIV is more 
efficient than cell free infection, this could be an essential method of virus production in vivo 
(Arthos et al., 2008). The blockade of the intergrin α4β7 by monoclonal antibodies affects viral 
replication of HIV in vitro, further supporting the role of the receptor in facilitating entry (Cicala 
et al., 2009).  However, a recent study by Parrish et al., (2012) found that transmitted viruses did 
not differ in their ability to bind CD4 and CCR5 compared to chronic viruses, and also found that 
anti- α4β7 antibodies were not effective at inhibiting infection.  Hence the transmission 
bottleneck does not seem to result in the selection of viruses that utilize CD4, CCR5, and α4β7. 
In conclusion, the role of the intergrin α4β7 during HIV mucosal transmission is yet to be fully 
understood, and the effect of the blockage of gp120- α4β7 interaction on HIV replication is not 
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1.8 HIV transmission 
 
1.8.1 Mucosal HIV transmission 
 
Sexual transmission accounts for the majority of HIV infections, with women being the worst 
affected by the epidemic (UNAIDS, 2011).  This thesis aims to understand viral factors that 
affect HIV transmission in a high risk population of women infected via the heterosexual 
transmission route.  Therefore, a detailed understanding of early events during HIV transmission 
and the nature of the incoming virus will aid  in interrupting HIV  transmission by vaccination, 
microbicides, and pre- or post-exposure prophylaxis. 
 
An intact vaginal epithelium consists of several thick layers of stratified squamous epithelial 
cells and the lamina propria, whereas the endocervix comprises of a single layer of columnar 
epithelial cells.  These layers of cells serve as targets for HIV entry and provide a mucosal 
barrier to HIV infection. This barrier does not provide absolute protection and the virus can 
move across the intact epithelial barrier. (Pope & Haase, 2003).  However, this barrier can be 
disrupted by  sexually tra smitted infections, microulcerations, and hormone-induced changes in 
the vaginal epithelium during the menstrual cycle (Hu et al., 2000).  This disruption can lead to 




 T cells cells to the submucosa enabling 
HIV infection and then rapid dissemination to the lymhoid tissues.  
Studies that have used the non human primate model have found that the infection is established 
in a small number of target cells that are infected by a small number of founder viral population. 
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mucosal tissue (Miller et al., 2005; Zhang, 1999).  This founder viral population was primarily 
identified in the endocervix and the transformation zone (which is the junction between ecto- and 
endocervix) (Haase, 2011; Sagar, 2010).  This period before peak viremia is known as the eclipse 
phase (Haase, 2011). The small founder population thereafter expands locally as a result of  
recruitment of additional target cells to the site of infection (Li et al., 2009a). The presence of 
virus results in an increase in MIP3-α/CCL20 expression by the endocervical epithelium, 
resulting in the recruitment of CCR6
+
 plasmacytoid dendritic cells to the site.  These dendritic 
cells in turn will secrete chemokines (which include MIP1α) resulting in the influx of T cells and 
macrophages.  This creates an environment that is rich in CD4
+ 
T cells, and making it favourable 
for the founder population to expand (Haase, 2011). However, the CD4
+
 T cells that are present 
in the cervical mucosa and submucosa show a ‘resting’ phenotype and low levels of CCR5 
expression (Li et al., 2005; Zhang, 1999).  It is suspected that these cells are memory T cells that 
have reverted to a ‘resting’ state but have CCR5 levels that are able to support HIV/SIV 
replication. The expansion will initially move to the draining genital lymph nodes for further 
expansion, and ultimately lead to systemic infection in the blood, gut, spleen via the thoracic 
duct (Haase, 2011) (Fig. 1.7).   
During the systemic stage of SIV and HIV infection, the innate immune response may or may 
not be able to control viral spread, and recruitment of more target cells could lead to further viral 
expansion.  This has been shown in acute systemic SIV infection that an increase in viral load is 
associated with the expression of the chemokines and interferon genes (Abel et al., 2005).  The 
duration of time before systemic spread to establish a clinical infection can have implications for 
the effectiveness of vaccines.  A vaccine may have a better chance of preventing viral replication 
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Furthermore, it may be important to limit the influx of target cells to the site of infection (Haase, 
2011).  In SIV, the lipid glycerol monolaurate has been shown to be effective in preventing 
transmission by preventing signalling and the influx of target cells (Li et al., 2009b).  If a large 
number of viruses infect a large number of CD4
+
 T cells and rapidly spread to the draining 
lymph nodes, then a vaccine will find it difficult to contain the infection even with a very rapid 
response.   
 
Figure 1.7. Illustration of the early events during HIV sexual transmission based on the rhesus macaque 
model. It is also shows phases of vulnerabilities which could be targeted by novel vaccines and microbicides ( 
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1.8.2 Isolation and enumeration of transmitted viruses 
 
Identification of the transmitted variant is ideally performed in the context of transmission pairs.  
However, due to the difficulties in identifying transmission pairs, together with problems in 
defining the transmitted/founder virus population; there have been various methodologies 
developed to derive the transmitted virus/founder virus responsible for clinical infections.  
Earlier studies that have investigated HIV transmission have used samples that were taken within 
the first six months of infection.  These studies used viral sequences that were isolated from 
plasma or peripheral blood mononuclear cells (PBMCs) by bulk PCR, and subsequent cloning, 
sequencing, and phylogenetic analysis (Derdeyn et al., 2004; Frost et al., 2005b; Learn et al., 
2002; Long et al., 2000; Ritola et al., 2004; Rusert et al., 2005; Sagar et al., 2003).  In some 
cases, the viral DNA was used to perform a Heteroduplex tracking assay (HTA), which involves 
the annealing of a short oligonucleotide probe to the amplified region of interest, and subsequent 
migration on a polyacrylamide gel.  The migration pattern of the DNA fragment was used to 
determine the extent of genetic diversity in a participant’s sample (Learn et al., 2002; Long et al., 
2000).   These methods have a number of limitations.  The method of bulk PCR and cloning is 
compromised by the introduction of errors by Taq polymerase and errors caused by template 
switching (Li et al., 2010; Palmer et al., 2005; Salazar-Gonzalez et al., 2008), resulting in 
extensive recombination (Salazar-Gonzalez et al., 2008; Shriner et al., 2004).  HTA allows for a 
more qualitative analysis of genetic diversity as it does not provide sequence data for 
phylogenetic analysis (Palmer et al., 2005; Salazar-Gonzalez et al., 2008).  
More recently, the single genome amplification (SGA) of viral RNA followed by direct 
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of viruses that have been transmitted, while also aim to address the limitations of previous 
approaches (Salazar-Gonzalez et al., 2008).  The method is based on dilution of the cDNA to an 
endpoint, where according on the Poisson distribution, a percentage of 30% or less of positive 
amplification enhances the probability of the products are derived from a single template. 
Sequences of these amplification products with no double peaks in the chromatograms were 
considered to be indicative of amplification from a single viral RNA template (Salazar-Gonzalez 
et al., 2009).  Using this approach on samples from acute infection,  Keele et al., (2008) 
developed a mathematical model of HIV sequence evolution which allowed for the identification 
of the transmitted/founder sequences based on an assumption that in the absence of selective 
pressure, the transmitted virus replicates exponentially and has a generation time of 2 days 
(Markowitz et al., 2003), has a reproductive ratio of 6 (Stafford et al., 2000), and an error rate of 
2.16 X 10
-5 
(Mansky, 1995), and also undergoes constant mutations in all positions and lineages 
without any back mutations.  The model showed that you could derive the transmitted/founder 
sequence at or near the time of transmission for sequences that fit this model of Poisson 
distribution of mutations and exhibits a star-like phylogeny (Keele et al., 2008).  
 
1.8.3 The population genetic bottleneck  
 
It has been widely shown that in the majority of cases, that there is a severe genetic bottleneck 
associated with HIV transmission (Zhu et al., 1992; Abrahams et al., 2009; Haaland et al., 2009; 
Keele et al., 2008; Salazar-Gonzalez et al., 2009).  Recent studies have shown that as much as 
76% and 78%  of sexual transmission events involve a single variant in both subtype B and C 
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transmission bottleneck (Abrahams et al., 2009; Keele et al., 2008).  Transmission of multiple 
genetically distinct variants does occur in approximately 20% of individuals and has been found 
to be associated with faster disease progression compared to those infected with a single genetic 
variant (Sagar et al., 2003).  However, the association between infection with multiple variants 
and disease progression was not observed in other studies (Abrahams et al., 2009; Woodman et 
al., 2011). 
There are various factors that may cause the bottleneck to be disrupted, which include genital 
tract infections and hormonal contraceptive use (Haaland et al., 2009; Sagar et al., 2003).  
Gender has also been shown to play a role in the degree of genetic diversity observed in 
individuals, with women being shown to be more susceptible to acquiring multiple genetic 
variants (Long et al., 2000), however,  this was not found in a study by  Abrahams et al., (2009).   
A high frequency of infection with multiple variants has been recently found in a population of 
men who have sex with men (Gottlieb et al., 2004; Li et al., 2010; Ritola et al., 2004). 
 
1.8.4 Characteristics of transmitted viruses 
 
Transmitted viruses have a number of biological features that are important during transmission, 
some of which may impact on subsequent disease progression.  The study reported in this thesis 
characterizes the phenotypic properties of the transmitted viruses and hypothesizes that certain 
properties within the Envelope protein of the transmitted viruses influences the disease outcome.  
 Despite the presence of R5 and X4 variants in the donor during chronic infection, variants that 
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al., 1999; Scarlatti et al., 1997) although viruses that utilize CXCR4 or both CCR5 and CXCR4 
have been identified in recently infected patients (Huang et al., 2007).  It has also been shown in 
donor-recipient transmission pairs that transmitted variants have Envelope proteins that are 
neutralization sensitive relative to the donor (Derdeyn et al., 2004), with shorter variable loop 
length and less N-glycosylation than the chronically infected patients (Chohan et al., 2005; 
Derdeyn et al., 2004; Sagar et al., 2006; Wu et al., 2006).  Similar results have been shown in 
Envelopes from subtype C transmission pairs (Haaland et al., 2009), subtype A (Chohan et al., 
2005), and subtype A and D transmission pairs (Sagar et al., 2006).  The authors argue that the 
less compact Envelope glycoproteins may be more efficient at interacting with target cells. 
However, this finding was not observed in subtype B heterosexual and MSM infections, 
suggesting that subtype differences in the virus can affect the efficiency of transmission (Chohan 
et al., 2005; Frost et al., 2005a; Wilen et al., 2012).  This phenotype was also observed in SIV 
infected macaques in which changes in N-linked glycosylation along with increasing VIV2 
length over time correlated with protection from neutralizing antibodies and loss of macrophage 
tropism (Rudensey et al., 1995). The transmitted virus from known transmission pairs was 
shown to be more compact and closer to the ancestral virus. (Redd et al., 2012). 
There has been a considerable effort in trying to identify unique signatures in transmitted viral 
sequences in comparison with chronic viral sequence.  Asmal and colleagues (2011) have 
recently found signatures near the CD4 and CCR5 binding sites, the gp41 cytoplasmic domain, 
and the signal peptide.  They found a significantly high frequency of a histidine residue at 
position 12 of the leader sequence amongst transmitted viral sequences.  This study showed that 
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the endoplasmic reticulum; and also have higher envelope expression and incorporation 
compared to those without the residue.  
A number of recent studies have investigated whether viruses from individuals with acute 
infection have the ability to use certain cell types and have a higher affinity for CD4 and CCR5 
receptors than chronic viruses.  Early viruses have been shown to be more sensitive to CCR5 
inhibitors than viruses at chronic infection, which suggests that transmitted viruses require high 
levels of CCR5 (Etemad et al., 2009).  The study also showed that transmitted viruses have 
slower fusion kinetics compared to those during chronic infection (Etemad et al., 2009). 
Transmitted viruses also have the ability to replicate efficiently in CD4
+
 T cells but poorly in 
monocyte-derived macrophages (Ochsenbauer et al., 2012; Salazar-Gonzalez et al., 2009).  This 
finding suggests that CD4
+
 T cells might be the main target cells and macrophages may not be 
critical during mucosal transmission as initially suspected.  
 
1.9 HIV-1 viral replication capacity  
 
1.9.1 Viral factors influencing viral replication capacity 
 
HIV-1 infected individuals that have the ability to control viremia without the use of antiviral 
therapy are known as HIV controllers.  These individuals maintain viremia at less than 2000 
RNA copies/ml, while those that maintain viral loads below 50 copies/ml are termed elite 
suppressors.  An understanding of the mechanism associated with this phenotype contributes to 
our understanding of HIV pathogenesis and could facilitate vaccine development.  There have 
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couples suggesting that properties of the virus may be inheritable (Alizon et al., 2010; Hecht et 
al., 2010; Hollingsworth et al., 2010; Tang et al., 2004; Yue et al., 2013).  A number of 
virological factors such as replicative rate, host cell tropism, linked to host factors which include 
genetic background, immune control, and target cell availability, have been associated with 
differential disease progression (Brockman et al., 2007; Chopera et al., 2008; Crawford et al., 
2007; Etemad et al., 2009; Lassen et al., 2009; Martinez-picado et al., 2006; Nicastri et al., 2003; 
Nijhuis et al., 1999; Ochsenbauer et al., 2012; Quiñones-Mateu et al., 2000; Salazar-Gonzalez et 
al., 2009; Schneidewind et al., 2007, 2008; Troyer et al., 2005). 
 
1.9.2 Differences in replicative fitness between subtypes 
 
Differences in pathogenicity and/or replicative fitness have been proposed to contribute to the 
uneven spread of HIV subtypes. A number of studies have compared in vitro replication between 
HIV Groups (Arie et al., 2005) and subtypes (Abraha et al., 2009; Rodriguez et al., 2009).  
Using pairwise competition experiments in PBMCs from various donors, HIV group M isolates 
of any subtype have 100-fold more replication capacity than group O or HIV-2 strains (Arie et 
al., 2005).  Similar findings were also observed in a study by Abraha et al., (2009) using an ex 
vivo transmission model.  The study hypothesized that the lower replication capacity of group O 
and HIV-2 viruses may be one of the reasons for the limited geographical spreading of these 
viruses.  Similar experiments were done comparing differences in replication fitness between 
HIV group M viruses.  Subtype C is the most successful subtype globally and there have been 
several studies to investigate if there are properties of this subtype that would promote its 
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in India, and found subtype C viruses have higher replication capacity than subtype A both in 
PBMCs and in  an ex vivo cervical tissue derived organ culture.  The authors propose that these 
findings may explain the uneven spread of subtype C over other subtypes in India.  In contrast, a 
study by Abraha et al., (2009) found that subtype C viruses have lower replicative fitness than 
subtypes B and D in an ex vivo transmission model using human explants from penile, rectal, and 
cervical tissues.  The authors proposed that subtype C may have equal transmission fitness, but 
have lower pathogenic fitness than the other subtypes.   However, caution must be exercised 
when extrapolating these laboratory results to what occurs in vivo. These in vitro replication 
models do not reflect the environment in vivo, and further some studies did not control for stage 
of infection from which the viruses were isolated from. As HIV rapidly evolves over time, these 
viruses would not reflect the properties of the transmitted/founder virus.  Furthermore, the 
growth competition assays utilize low numbers of representative viruses, thus making subtype 
specific comparisons of viral fitness very difficult to interpret.  Therefore, the role of replicative 
fitness in the pathogenicity and spread of HIV subtypes remains controversial. 
Clinical studies have also been performed, which measures the association between being 
infected with a particular subtypes and the rate at which an individual will progress to disease 
(Kaleebu et al., 2002; Kiwanuka et al., 2008).  A number of clinical studies that were done in 
Uganda found that individuals infected with subtype D, inter-subtype recombinants, and multiple 
subtypes progressed more rapidly to AIDS and death, compared to individuals infected with 
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1.9.3 The association between viral replication capacity and disease progression  
 
Viral fitness describes an virus’ ability to replicate in a particular environment and is partly 
influenced by the efficiency at which the virus is able to enter and infect host cells (Quiñones-
Mateu et al., 2000).  Recent studies have found an association between viral replication capacity 
and disease progression, and this association has been found in viruses that are isolated during 
chronic infection (Lassen et al., 2009; Miura et al., 2009a; Quiñones-Mateu et al., 2000).  HIV-1 
isolates from individuals that have progressed slowly to disease showed a significantly lower 
replicative fitness compared to patients with accelerated progression to AIDS (Quiñones-Mateu 
et al., 2000). Miura and colleagues (2009) also demonstrated that elite controllers are infected 
with variants with lower replication capacity than those carried by rapid progressors.  The escape 
mutations in Gag, particularly in the p24 capsid region, carry a fitness cost to the virus as these 
mutations may affect the conformation of the viral capsid (Chopera et al., 2012; Martinez-picado 
et al., 2006; Schneidewind et al., 2008; Wright et al., 2011).  They have been associated with 
lower viral load and delayed disease progression in a number of cohorts (Brockman et al., 2010; 
Chopera et al., 2008; Crawford et al., 2009; Prince et al., 2012; Wright et al., 2011).   HIV 
controllers also harbour viruses that have low Envelope entry efficiency, suggesting that there 
are also determinants in Envelope that influence viral fitness and disease outcome (Lassen et al., 
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1.9. 4 The effect of coreceptor switching on viral replication capacity 
 
Individuals that are infected with certain subtypes such as subtype C (Morris et al., 2001; Peeters 
et al., 1999) rarely harbor viruses that use CXCR4. In subype B infections,  the process of 
coreceptor switching occurs in 40 to 50% of individuals infected (Karlsson et al., 1994; Koot et 
al., 1993).  A transition from a CCR5 utilizing (R5) phenotype to a CXCR4 (X4) phenotype is 
associated with increased replication capacity and progression to AIDS (Troyer et al., 2005).  
 
1.9. 5 Evolution of viral replication capacity over time 
 
There have been conflicting findings regarding the evolution of HIV-1 replicative fitness over 
time. Arie et al., (2005) found that historical HIV isolates (isolated between 1986 and 1989) had 
a higher replicative fitness than recent HIV isolates (isolated between 2002 and 2003), 
suggesting that HIV virulence has attenuated over time.  However, a similar study in Amsterdam 
found an increase in HIV replicative fitness over time when early isolates (from 1986) were 
competed head–to–head with late viral isolates (from 1996-2003) (Gali et al., 2007).  A recent 
study by Gras et al., (2010) compared differences in viral loads in ARV-naïve subjects that 
seroconverted at various time points, which include 1984 to 1995, 1996 to 2002, and 2003 to 
2007.  This study found that subjects that seroconverted between 1984 to 1995, and 1996 to 
2005, had significantly lower viral loads and CD4 count at viral set point than those that 
seroconverted between 2003 and 2007.  These findings may suggest an increase in viral 
replication capacity over time in the Netherlands.  An increase in viral load and decrease in CD4 
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in North America did not find any change in virulence (Herbeck et al., 2008).  It is very difficult 
to interpret or make comparison between these studies because of differences in laboratory 
techniques that were used, which may affect the assay readout.  Therefore, the evolution of HIV 
replication capacity over time still remains unclear. 
 
1.10 Study rationale 
 
An understanding of early events that are involved during transmission, and the phenotype of the 
transmitted variant, is important for vaccine development which needs to block the incoming 
transmitted viruses.  Recent studies have shown that there is evidence of a viral population 
bottleneck that occurs during transmission, resulting in the transmission of a single variant in 
approximately 80% of cases (Abrahams et al., 2009; Haaland et al., 2009; Keele et al., 2008). 
These studies were done in subtype B and C cohorts and also in regions where only a single 
subtype is circulating. Due to previous findings that HIV subtypes can be a determinant of the 
rate of disease progression (Baeten et al., 2007; Kaleebu et al., 2002; Kiwanuka et al., 2008; 
Kuritzkes, 2008), there is a need to understand the transmission characteristics  in a region that 
has multiple subtypes that  are co-circulating.  Therefore, the aim of this study was to 
characterize the genotypic and phenotypic properties of transmitted viruses that are circulating in 
Mbeya Tanzania, which is region that has a number of HIV subtypes and recombinants. 
A number of studies have shown that the env gene plays a major role in the competitive and 
adaptive ability of the virus (Ball et al., 2003; Rangel et al., 2003; Travers et al., 2005) and that 










Chapter 1: Introduction and Literature Review 
   40 
 
2009; Marozsan et al., 2005) and subsequent disease progression (Quiñones-Mateu et al., 2000). 
Therefore, the study aims to determine if there are properties in the HIV-1 Envelope responsible 
for clinical infection that may impact subsequent disease progression. 
This study forms part of the Mbeya Medical Research Programme, and was conducted using 
twenty-two acute infection plasma samples from a high risk population in the Mbeya region of 
Tanzania.  These participants were followed up every three months for over 3 years as part of 
HIV Superinfection Study (HISIS) cohort (Hoelscher et al., 1998; Riedner et al., 2006).  
The specific objectives of the project were as follows: 
1. To characterize the virus population bottleneck in recently infected individuals from Mbeya, 
Tanzania.  
2. To compare and characterize differences in Envelope entry efficiency of transmitted viruses 
circulating in the region. 
3. To determine the association between host cell entry efficiency and disease progression. 
4. To investigate the relationship between entry efficiency and replicative capacity of 
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The Mbeya region of Tanzania has a genetically complex HIV epidemic with multiple subtypes 
and recombinant forms circulating, together with a high frequency of dual infections with more 
than one subtype.  This study aimed to determine whether this impacted the HIV-1 transmission 
bottleneck.  A total of 122 env sequences from 14 participants were generated from recently 
infected women from Mbeya using the single genome amplification approach.  These were 
combined with 88 sequences that were available from the laboratory yielding a total of 210 from 
22 participants.  The subtyping and multiplicity of infection was determined using phylogeny, 
together with the mathematical model of random evolution.  Participants were infected with 
subtypes C (n = 9), A (n = 4), or D (n = 1); and recombinants AC (n = 4), CD (n = 2), AD (n = 
1), or ACD (n = 1).  In sixteen participants (73 %) clinical infection was the result of a single 
variant; whereas in five (23 %) participants there was evidence of multiple variant infection with 
more than one closely related quasispecies; and one (4 %) participant was found to be dually 
infected.  Thus the frequency of single variant infections was similar to cohorts located in 
genetically restricted subtype B or C epidemics, suggesting that multiple circulating subtypes 
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The extensive HIV-1 genetic diversity is one of the major obstacles in the development of an 
effective vaccine.  In order for a vaccine to be effective, it will need to prevent the spread of the 
virus from the mucosal surfaces to the neighboring lymph nodes, and ultimately systemic spread 
of infection.  A number of studies have shown that there is evidence of viral population 
bottleneck that occurs during transmission, and a single variant gets transmitted to establish 
clinical infection in approximately 80 % of cases (Abrahams et al., 2009; Haaland et al., 2009; 
Keele et al., 2008).  This finding presents a small ‘window of opportunity’ for vaccine 
development as the vaccine will need to be effective against viruses with low genetic diversity 
during acute infection.  
Recently, Keele and colleagues (2008) developed a mathematical model of HIV sequence 
evolution during acute infection that allows for the identification of the transmitted/founder 
sequences during acute infection. According to the model, the transmitted/founder sequences 
show a Poisson distribution and a star-like phylogeny which coalesce into a transmitted/founder 
genome at or near the time transmission occurs. This model accounts for a number of factors 
such as the rate of virus growth, reproductive ratio, virus generation time, and the reverse 
transcriptase error rate (Lee et al., 2009). This model assumes early collection of sample and 
therefore limited sequence changes due to selection. Also, the consensus that is derived from the 
sequences that are samples before the onset of an immune response is the transmitted/founder 
virus that is responsible for establishing clinical infection.  However, in cases where multiple 
viruses are transmitted, the viral sequences do not follow a Poisson distribution, and this implies 
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2008). These multiple transmission events vary between individuals and occur independently to 
each other, which may suggest that other factors such as STIs and hormonal contraceptives 
might play a role (Haaland et al., 2009). 
This approach allowed for the most recent common ancestor to be predicted, and was 
subsequently supported by both non-human primate and human studies.  A study by Keele et al., 
(2009) found that the viral env sequence in a newly infected Indian rhesus macaque was identical 
or differed by a few nucleotides to the virus in the inoculums.  Another study by Haaland et al., 
(2009) done on human transmission pairs also found the HIV env and full-length genomic 
sequences to be either identical of differ by a few amino acids in V1-V3 region in both donors 
and recipients. 
 The population genetic bottleneck has only been shown in regions where only a single subtype 
is prevalent.  A number of studies have shown that HIV subtype can be a determinant of 
transmission efficiency and rate of disease progression (Baeten et al., 2007; Kaleebu et al., 2002; 
Kiwanuka et al., 2008; Kuritzkes, 2008).  Also, the genetic diversity at transmission has been 
previously associated the rate of disease progression (Sagar et al., 2003). Therefore it is 
important to understand the impact of the population genetic bottleneck in a region where there 
are multiple subtypes that are circulating.  Therefore, this study aimed to characterize the genetic 
bottleneck of transmitted variants infecting a Tanzanian cohort of high risk women. The region 
of Mbeya has multiple subtypes, which include subtype A, C, and D, a high number of unique 
recombinant viruses, as well as a high frequency (18%) of dual infection providing an 
opportunity to investigate if a genetically diverse HIV-1 epidemic impacts on the transmission 
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2.2. MATERIALS AND METHODS 
 
2.2. 1 Cohort description 
 
Plasma was obtained from 22 participants from a high-risk population of female bar workers in 
Mbeya, Tanzania.   Recently infected individuals were identified from an HIV-1 uninfected 
cohort who were screened every three months for the presence of HIV antibodies and/or RNA as 
part of a prospective HIV superinfection study (HISIS) (Ethics number: 168/2007) (Geldmacher 
et al., 2007; Herbinger et al., 2006; Hoelscher et al., 2001; Riedner et al., 2006)  using the 
EnzygnostAntiHIV ½ Plus (Dade Behring, Liedrebach, Germany) and Determine HIV ½ 
(Abbott, Wiesbaden, Germany). Plasma RNA levels were measured using the Amplicor HIV 
Monitor Assay (Roche Diagnostics, Indianapolis, IN).   The duration of HIV-1 infection was 
categorized into five stages based on evolving HIV-1 RNA or antibody profiles (Fiebig et al., 
2003).  Individuals classified as being in Stage I/II were viral RNA positive, ELISA antibody 
negative; those in stage III were ELISA antibody positive but negative by Western blot; those in 
stage IV had an indeterminate Western blot; those in stage V were Western blot positive but 
without reactivity to the p31 integrase band; and those in stage VI were Western blot positive 
with a p31 band present.  Western blots were performed using the GS HIV-1 Western Blot kit 
(Biorad, WA, USA) by Mrs R. Thebus at the University of Cape Town. The date of infection 
was estimated based on p24 antibody reactivity, western blot analysis of the seropositive samples 
and the time since the last seronegative using the algorithm in the study by Fiebig et al., (2003) 
and Keele et al., (2008). Therefore, Fiebig stages I/II was dated as 14 days post infection, Fiebig 
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midpoint between the last seronegative and the first seropositive visit. This analysis was done by 
Mr. Gama Bandawe at the University of Cape Town.  
2.2.2 Amplification and sequencing 
 
2.2.2.1 RNA extraction and cDNA synthesis 
 
RNA was extracted from the plasma samples using the MagNA Pure Compact RNA isolation kit 
(Roche, Germany).  Complementary DNA was synthesized using the Superscript III™ RT-PCR 
System Kit (Invitrogen, GmbH, Karlsruhe, Germany) using the OFM19 primer (5’ GCA CTC 
AAG GCA AGC TTT ATT GAG GCT TA 3’) as described (Salazar-Gonzalez et al., 2008). 
2.2.2.2 PCR amplification using Single Genome Amplification (SGA) method 
 
 The resulting cDNA was amplified using Single Genome Amplification (SGA) approach as 
described (Abrahams et al., 2009; Keele et al., 2008).  The full-length env sequences (2590 bp) 
were amplified from 22 participants with acute/early infection patient samples from Tanzania by 
using the Single Genome Amplification (SGA) approach (Salazar-Gonzalez et al., 2008).  This 
method involves diluting the cDNA in a two step nested PCR reaction so that initial 
amplification occurs from a single viral RNA template.  According to the Poisson, if the percent 
of positive amplification product is 30% or less, it is likely to have been amplified from a single 
RNA template. The entire positive env amplification product is sequenced to determine whether 
there is a homogenous population in the reaction mix by detecting the presence of double peaks 
in the chromatograms. The absence of double peaks is indicative of sequence homogeneity.  
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in a test tube by bulk PCR.  In addition, as each amplicon represents one amplifiable copy, it also 
ensures that sequences generated are representative of the variants present in the sample.  
The amplification of the HIV-1 env by SGA was developed for HIV subtype C viral templates 
(Abrahams et al., 2009).  As Mbeya has multiple subtypes including subtypes A, C, and D, as 
well as recombinant forms, the initial phase of the study was to test whether the SGA primers 
designed for subtype C could amplify and sequence other subtypes.  The primer sequences were 
submitted to PrimAlign (www.HIV.lanl.gov), to identify the homology of the primer sequences 
to subtype reference sequences in the database.  The primer sequence was found to be 
complimentary subtype A, C, D, along with recombinant forms in the database with few 
nucleotide polymorphisms.  These primers were found to reliably amplify the env region from all 
samples, which include subtype A, and a number of AC, CD, and AD recombinant viruses.  Thus 
far, the patient samples had been successfully amplified using single genome amplification 
(SGA).  
 The cDNA was serially diluted and used for the first round PRC amplification.  The first round 
PCR reaction mix for a 1X reaction include 10X Hi-Fi Buffer (Invitrogen, CA, US), MgSO4 
(Invitrogen, CA, US), DNTPs (10 mM each), 20 µM of both forward primer OFM19 (5’ GCA 
CTCAAGGCAAGCTTTATTGAGGCTTA 3’) and reverse primer VIF1 (5’ GGG TTT ATT 
ACA GGG ACA GCA GAG 3’), Taq High Fidelity Platinum polymers (Invitrogen, CA, US), 
and distilled water was added up to a final volume of 20 µl.  The  samples were placed in a 
thermal cycle and the reaction was run under the following conditions: 94ºC for 2 minutes, 35 
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The first round amplicon (1µl) was used for the second round (nested) PCR reaction.  The PCR 
reaction mix for a 1X reaction included 10X Hi-Fi Buffer (Invitrogen, CA, US), MgSO4 
(Invitrogen, CA, US), dNTPs (10 mM each), 20 µM of both forward primer EnvA (5’ 
(CACC)GGC TTA GGC ATC TCC TAT GGC AGG AAG AA 3’) and reverse primer EnvN (5’ 
CTG CCA ATC AGG GAA GTA GCC TTG TGT 3’), Taq High Fidelity Platinum polymerase 
(Invitrogen, CA, US), and distilled water was added up to a final volume of 20 µl.  The  samples 
were placed in a thermal cycle and the reaction was run under the following conditions: 94 ºC for 
2 minutes, 45 cycles of  55 ºC for 30 seconds, 68 ºC for 30 seconds, and  1 cycle of 68 ºC for 20 
minutes.  The PCR product (3 μl) was loaded onto a 0.8 % agarose gel and migrated at 100V for 
1 hour. 
2.2.3 Intra-patient quasispecies diversity 
 
Generation of phylogenetic trees and computation of pairwise DNA distances were done using 
MEGA version 4 (Tamura et al., 2007) and differences were visualized using transition and 
transversion plots in the HIGHLIGHTER plots (www.hiv.lanl.gov).  Sequences were analyzed 
for evidence of APOBEC3G-induced hypermutation using Hypermut 2.0 tool 
(www.hiv.lanl.gov). 
2.2.4 Sequence analysis 
 
Sequences of the full-length envelope gene were assembled and edited using the Sequence 
Assembly Pipeline (http://tools.caprisa.org).  The sequences were aligned by the ClustalW 
application in the BioEdit Sequence Alignment Editor.  Twenty-eight reference sequences 
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phylogenetic trees.  Phylogenetic trees constructed using the Neighbor-Joining method using 
MEGA 4 (Tamura et al., 2007).  The tree was constructed with 500 bootstrap replicates, with 1st, 
2nd, 3rd codon positions as well as non-coding sites included, and the maximum composite 
likelihood nucleotide model was used.  The REGA HIV Subtyping Tool Version 2.0 
(http://www.bioafrica.net) was used for subtyping. Maxchi, Chimaera, and Bootscan analysis 
using RDP v3.34 (http://darwin.uvigo.es/rdp/rdp.html) (Martin et al., 2005) was used to detect 
inter- and intrasubtype recombination events, and a bootstrap value equal to or greater than 70% 
was considered as significant.   Recombination analysis was performed with a window size of 
400 and step size 20. 
2.2.5 Estimation of time to most recent common ancestor (tMRCA)   
 
We used a Bayesian Markov Chain Monte Carlo method implemented in Bayesian Evolutionary 
Analysis Sampling Trees (BEAST) v1.4.7 (Drummond & Rambaut, 2007)  which uses SGA-
derived sequences to estimate the time to most recent common ancestor (tMRCA).  This is based 
on the assumption that in the absence of selective pressure, the transmitted/founder virus 
replicates exponentially and has a generation time of 2 days (Markowitz et al., 2003), has a 
reproductive ratio of 6 (Stafford et al., 2000), and an error rate of 2.16 X 10
-5 
(Mansky, 1995), 
and also undergoes constant mutations in all positions and lineages without any back mutations.  
2.2.6 Immune escape analysis 
 
The identification of potential epitopes for analysis of cytotoxic T-lymphocyte (CTL) escape was 
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2.3.1 Cohort description 
 
Twenty-two participants were recruited within three months of their previous HIV negative 
sample (Herbinger et al., 2006; Riedner et al., 2006). This work was at the Mbeya Medical 
Research Clinic as part of the HIV superinfection study (HISIS) work in Mbeya, Tanzania 
(Geldmacher et al., 2007; Herbinger et al., 2006; Hoelscher et al., 2001; Riedner et al., 2006) 
(Table 2.1).  Laboratory staging based on evolving viral RNA and antibody profiles was 
performed on 20 of the plasma samples (Fiebig et al., 2003) by Mrs R Thebus at the University 
of Cape Town.  Of these, 3 were in the acute/early stage of primary infection (Stage I-IV) and 17 
individuals were in the later stage of primary infection (Stage V-VI).   As expected the viral 
loads were higher for individuals with acute/early infection (median >750 001 copies/ml), 
compared to the 17 participants in later stages of primary infection (Stage V-VI) (median = 66 
000 copies/ml) (Table 2.1).  The estimated number of days post-infection ranges from 14-45 
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Table 2.1 Data summary of 22 participant samples from a high risk population of female bar workers from Mbeya, 
Tanzania. The study participants are grouped based on whether they are infected with either single or multiple 
viruses.  




















95% CI  
89-F1 I/II 14 750 001 CD 10 0 0 0 0 
216-F2 VI 14 1 840 A 7 0 0 0 0 
49-F1 III 30 750 001 ACD 11 0.08 8.008 0.61 22.476 
234-F1 V/VI 45 509 000 C 12 0.12 13.524 2.902 32.046 
390-F1 V 45 750 001 C 11 0.23 23.89 9.902 56.9 
401-F1 ND 45 51 500 CD 6 0.24 24.61 8.874 73.046 
304-F2 V 45 750 001 C 11 0.23 31.625 17.486 58.102 
54-F4 VI 41 28 200 D 9 0.27 45.006 27.83 79.512 
605-F4 V/VI 41 434 000 AC 9 0.42 48.466 28.406 83.512 
515-F4 VI 41 3 660 A 5 0.27 48.456 16.726 126.648 
569-F1 V/VI 45 23 800 C 11 0.2 57.524 24.534 114.418 
246-F3 VI 42 439 000 AC 18 0.27 62.442 36.166 90.62 
*346-F4 VI 41 26 700 C 8 0.23 78.238 28.164 155.58 
541-F1 VI ND 66 100 C 11 0.29 100.124 55.526 162.136 
*398-F1 ND 45 2 370 A 8 0.39 185.108 88.356 354.172 
556-F3 V 44 43 300 C 11 1.45 365.69 188.84 792.366 
142-F3 VI 44 366 000 C 9 1.56 469.844 289.914 720.324 
98-F4 V 41 5 330 C 6 2.37 743.098 884.858 1615.466 
21-F1 V/VI 42 21 200 C 11 0.97 1505.424 715.594 2957.18 
532-F0 I/II 14 2 370 AD 10 1.18 1952.874 762.08 4313.646 
410-F2 VI ND 165 000 C/AC 11 4.61 2104.35 933.334 4767.876 
* denotes participants that have diversified from single lineage based on shared mutations that are attributed to CTL and/or antibody pressure 
** as according to Fiebig et al., 1993 
MRCA – Most Recent Common Ancestor; GT – Generation Time; CI – Confidence Intervals; ND – not done 
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2.3.2 HIV subytping and phylogenetic analysis 
 
To investigate the extent of genetic diversity in a cohort of high risk women from Mbeya, the 
single genome amplification followed by sequencing was used.  A total of 122 env sequences 
from 14 participants were generated from recently infected women from Mbeya using the single 
genome amplification approach.  These were combined with 88 sequences that were generated 
from 8 participants (provided by G. Bandawe University of Cape Town) to make up a total of 
210 from 22 participants.  The env sequences from 20 of the 21 participants formed 
monophyletic clusters that showed that these participants were singly infected, while one 
participant (410-F2) had sequences that formed two distinct phylogenetic lineages, which 
suggests that the participant was dually infected with two distinct subtypes or RFs (Fig. 2.1).  
The majority (14 out of 22 participants) of env sequences were identified as pure subtype with 
nine participants infected with subtype C, four with subtype A, and one with subtype D.  Eight 
participants were found to be infected with intersubtype recombinant viruses , of which four 
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FIGURE 2.1 Neighbor-joining tree indicating the subtype distribution from 212 env sequences from 22 
participants. The tree was constructed using the Dendroscope progam (http://ab.inf.uni-tuebingen.de/soft 
ware/dendroscope/). The colours representing the various subtype in the participants’ sequences, which is subtype C 
(red), D (blue), and AC, AD, CD, and ACD intersubtype recombinants (pink).  The dually infected participant 410 
who was infected with subtypes C and AC is circled. The tree was rooted using sequences from subtypes F, K, H, 
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The recombination analysis identified eight participants were infected with intersubtype 
recombinant viruses.  Two participants (89-F1 and 401-F1) were infected with CD 
recombinants, four participants (246-F3, 410-F2, 477-F3, and 605-F4) were infected with AC 
recombinants, one participant (54-F4) with AD recombinant, and one participant (49-F1) was 
infected with an ACD recombinant (Fig. 4).  One of the participants, 410-F2, had a region in 
gp41 that was identified as subtype G by the REGA HIV Subtyping Tool, however, further 
analysis using BLAST (http://www.ncbi.nlm.nih.gov/blast) and RDP v3.34  identified  the region 
as being subtype A. Therefore, we classified the virus as an AC recombinant (Fig. 2.5).  All RF 
sequences from each participant were unique and did not share mosaic structures with viruses 
from other participants (Fig. 2.2) or any other recombinant forms from the East African region 
(data not shown).  In addition, with the exception of participant 410-F2, all the viruses obtained 
from a given participant shared the same recombination mosaic structure with no variation in 
recombination breakpoints suggesting that these individuals were infected with the recombinant 
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          Participant 49-F1 (ACD recombinant)                           Participant 89-F2 (CD recombinant) 
                      
       Participant 246-F4 (AC recombinant)                 Participant 401-F1 (CD recombinant) 
                       
          
         Participant 410-F2 (AC recombinant)                  Participant 477-F3 (AC recombinant)                                                                     
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            Participant 532-F0 (AD recombinant)                           Participant 605-F4 (AC recombinant) 
                   
 
Figure 2.2 Recombination analysis of env sequences from eight participants. Participant 49-F1 was infected 
with an ACD recombinant, Participant 532-F0 was infected with an AD recombinant, Participants 89-F2 and 401-
F1 were infected with CD recombinant viruses, and Participants 605-F4, 477-F3, 246-F4, and 410-F2 were infected 
AC recombinant viruses.  The recombination analysis was done using Bootscan within RDP 3.34. (Martin et al., 
2005) (below) and REGA HIV-1 Subtyping Tool (above).  The recombinants are shown to be derived from subtypes 
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2.3.4 Single and multiple variant transmissions 
 
The study used a number of methods to define single and multiple variant transmission events 
amongst the participants. We defined single variant infection as sequences with low quasispecies 
diversity with a star-like phylogeny which would be expected for sequences from individuals 
infected with a single variant which undergoes neutral evolution prior to the onset of immune 
pressure (Keele et al., 2008).  In addition, for single variant infection the time of divergence from 
the most recent common ancestor (MRCA) should fall within 90 days since the last HIV 
negative blood sample.  The MRCA analysis was done by Natasha Wood and Gama Bandawe at 
the University of Cape Town. 
Based on this criterion, thirteen participants were found to be infected with a single virus. The 
viral populations in these participants had maximum pair-wise DNA distances ranging from 0 % 
to 0.42 % with concomitant lack of structure in the neighbor-joining phylogenetic trees. 
A further three  participants (346-F4, 398-F1 and 477-F3) were regarded as being infected with a 
single variant as even though they showed some structure in the phylogenetic tree.  These 
individuals were classified as infected with a single variant as these sequence changes could be 
accounted for by cytotoxic T-lymphocyte and/or antibody pressure.  Participant 398-F1 who 
showed both CTL escape in a predicted epitope restricted by the participants HLA (A*6802), as 
well as antibody selection.  Sequences from participant 346-F4 had an estimated tMRCA of 78 
days, while participant 398-F1 had an estimated tMRCA of 185 days.  The high estimated 
tMRCA is likely due to CTL escape driven diversification (Fig. 2.6).  For participant 477-F3, we 
were only able to amplify sequences from the third follow-up visit, although there was evidence 
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respectively).  Sequences from this participant had a maximum DNA distance of 0.68 % and in 
line with estimated time of infection, the mean tMRCA of 324 days was estimated (Table 2.1).  
While it was not possible to resolve the infecting virus from this individual, she was classified as 
infected with a single variant as many changes of the sequences shared the same mutations 
which could be accounted for by both CTL and antibody selection (Fig. 2.6).  Therefore, 16 out 
of 22 participants (73%) were classified as infected with viruses with a single variant (Table 
2.1). 
Participants were identified to be infected with multiple variants if there was high diversity 
together with monophyletic cluster with distinct structure in Neighbor joining trees (Fig. 2.3).  
Whereas, participants were classified as dual infected if infected with two distinct virus strains 
which could be separated on phylogenetic trees with epidemiologically unlinked viruses.  Our 
expectation was that for multiple variants or dual infection transmission, the sequences in the 
recipient should coalesce at a time pre-dating the last seronegative visit (approximately 90 days 
prior to first seropositive visit) based on the estimated tMRCA. Five participants (23 %) were 
found to be infected with multiple variants and one with dual infection (4 %).  In these 
participants, the maximum pair-wise DNA distances ranged from 0.97 % to 2.37 %. As a result 
of their extensive diversity, three participants (21-F1, 556-F3, and 142-F3) showed evidence of 
intrapatient recombination (Fig. 2.4).  In all five participants, the estimated number of days since 
the MRCA significantly exceeded the period for which the associated individual could 
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Figure 2.3 Neighbor-joining and Highlighter analyses that show the type of transmission event observed amongst 
the participants. Participant 304-F2 illustrates evidence of single variant transmission, and participant 556-F3 shows 
evidence of multiple variant transmission, and also the resulting recombination between viral lineages. The ticks in 
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A. Participant 21-F1                                                           B.  Participant 556-F2 



























C. Participant 142-F3 











   
Figure 2.4. Neighbor-joining tree showing evidence of intrasubype recombinant observed in three 
participants (21-F1, 142-F3, and 556-F2). Virus A and B represented the parental viruses and virus A/B represent 
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2.3.5 Dual infection 
 
The presence of various subtypes in this region has also resulted in dual infections, with a 
frequency as much as 18% in this region (Herbinger et al., 2006).  By means of phylogeny 
analysis, the study aims to identify any evidence of dual infection amongst the participants. 
Participants were classified as dual infected if infected with two distinct virus strains which 
could be separated on phylogenetic trees with epidemiologically unlinked viruses.  One of the 
participants 410-F2 was found to by dually infected (Fig. 2.1). Subtyping analysis of the 
participant sequences showed one subtype C population and the other being an AC recombinant. 
The gp120 regions of the two viral populations showed homogeneity with a maximum DNA 
distance 0.16 %, with a single recombination breakpoint in gp41.  Phylogenetic analysis based 
on gp41 sequences showed two separate lineages clustering with high bootstrap support (Fig. 
2.1).  The sequences in the gp41 region differed by as much as 4.6 %.  The number of sequences 
that were generated from this participant allowed for the identification of only one parental 
sequence, which is the subtype C virus.  The other sequence, which is an AC recombinant, 
appears is likely to be a progeny virus that is derived from the subtype A and C parental viruses. 
In the absence of the other parent, it remains unclear as to whether this individual was originally 
infected with both subtype A and C viruses, with the generation of the AC recombinant 
occurring post infection; or whether co-transmission of the C and AC recombinant virus 
occurred from a dually infected donor. 










Chapter 2: Characterization of the HIV-1 transmission bottleneck in recently infected individuals from Mbeya, 
Tanzania 
   63 
 




















                                              
 
Figure 2.5. Neighbor-joining and Highlighter analyses from the dually infected participant participant 410-
F2. This participant was infected with subtype C and with an AC recombinant.  The ticks in the HIGHLIGHTER 
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Figure 2.6.  Putative CTL pressure (red blocks) in participants 346-F4 (A), 477-F3 (B) and 398-F1 (C) shown 
by Neighbor  Joining phylogenetic trees and HIGHLIGHTER analyses. Epitope Location Finder 
(www.hiv.lanl.gov) and Net MHCpan 2.0 server (www.cbs.dtu.dk) were used to identify known or predicted HLA 
class I associations are shown along with the known or predicted HLA restriction for each participant.  Putative 
antibody pressure (mutations in N-linked glycosylation sites) is shown in black blocks.  Putative CTL epitopes. 
colours in the HIGHLIGHTER plot for participants 477 and 398 represent the following: A: green, T: red, G: 
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This study aimed to determine the frequency of the population transmitted/founder bottleneck in 
the cohort of high risk women in Mbeya region of Tanzania.  This cohort has been previously 
known to be infected with a number of subtypes A, C, D; along with a number of intersubtype 
recombinants.  The population bottleneck has been investigated in other cohorts (Abrahams et 
al., 2009; Keele et al., 2008), but only in region where there is a single subtypes that is 
circulating, mainly in subtype C and B cohorts. The study founds in the HISIS cohort a 73 % 
frequency of single variant transmission event, compared to a frequency of 76 % (Keele et al., 
2008) and 78 % (Abrahams et al., 2009) that has been shown in other studies.  Therefore, these 
findings illustrate that subtype differences does not seem to have an impact on the transmission 
bottleneck.  It must be noted that the studies by (Abrahams et al., 2009; Keele et al., 2008) used 
20 or more sequences to investigate the transmission bottleneck.  Based on the power analysis in 
a study by (Keele et al., 2008), this would allow for a 95 % probability to detect sequences that 
are present at a frequency of more than 15 %.  Our study only used 10 sequences per participant 
which only allowed for an overall probability of 80%, and therefore this should be taken into 
consideration.  
We found a high frequency of subtype C infections in the participants, both as the infecting 
subtype in the majority of participants and also certain regions of it being present in recombinant 
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subtypes that circulate in the region with a high percentage of intersubtype recombinants.  This 
subtyping profile is similar to a previous study which used a multi-region hybridization (MHA) 
assay to identify the subtypes (Herbinger et al., 2006). There was a relative dominance of 
infection with subtype C, which was found in 45 % of the individuals. The recombination 
analysis also found that all the recombinant viruses have regions that are derived from subtype C. 
Also, similar to the findings by (Hoelscher et al., 2001),  the recombinant viruses were shown to 
be unique and more sampling would be needed to determine if they are spreading in the region. 
This study identified only one participant with dual infection out of the 22 participants (4 %) that 
were screened.  This frequency is much lower compared to the frequency of 18% that has been 
previously found in this cohort (Herbinger et al., 2006), which used the MHA method to screen 
for dual infections.  Despite not being able to detect certain strains due to occasional primer or 
probe mismatch, the MHA was more sensitive at identifying the dual infections than the SGA 
approach which we used an average of 10 sequences per participant and also used only one 
region to detect dual infection, as opposed to the MHA which uses multiple genes in HIV 
genome.  However, the increased prevalence of dual infection in the study by (Herbinger et al., 
2006) could be due to the fact that these authors were detecting both co-infection and 
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In conclusion, similar approaches to other studies, this study found that the population 
transmission bottleneck remains constant in heterosexual transmissions irrespective of the 
geographical region or the complexity of the circulating viruses. These findings have 
implications  on vaccine design as vaccines that aim block transmitted viruses can be effective 
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A better understanding of the biological characteristics of transmitted viruses will provide 
important insights into HIV pathogenesis and aid in vaccine development.  The aim of this study 
was to determine the relationship between viral entry efficiency and disease progression and to 
characterize the Envelope function of transmitted/founder (T/F) viruses representative of 
different subtypes and recombinant forms. HIV-1 Envelope pseudoviruses, representative of 
subtypes C (n = 6), D (n = 1) and recombinants CD (n = 2) and AC (n = 1), that matched the 
consensus of single genome derived sequences from early infection ere generated.  These 
molecular clones, assumed to represent the founder virus responsible for clinical infection, had a 
>100 fold range in entry efficiencies.  An association was found between entry efficiency and 
viral load at 3 months (p = 0.0022) and 12 months postinfection (p = 0.0347) suggesting that 
viruses carrying Envelope with enhanced entry function at transmission may influence 
subsequent disease progression. Using the HEK 293 Affinofile cells to measure entry efficiency,  
the relative Envelope entry efficiency of the T/F viruses was shown to be dependent on both high 
CD4 and CCR5 levels (CD4  levels = 146 397 molecules/cell; CCR5 levels = 428 032 
molecules/cell) as only 30 % of the viruses were able to mediate entry of cells with low levels of 
CD4 ( CD4 levels = 3 041 molecules/cell) , and absolute entry efficiency levels dropped 4 to 5-
fold when CCR5 levels were lowered to 2 566 molecules/cell. The ability of the pseudoviruses to  
enter cells with low CD4 and CCR5 levels was significantly associated with the IC50 values for 
soluble CD4 (p = 0.0438) and CCR5 antagonist, TAK779 (p = 0.0138), suggesting that receptor 
affinity contributed to these differences in entry efficiency.   Furthermore, some viruses with 
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those with low entry efficiency, suggesting that surface Envelope expression may also influence 
entry efficiency.  This data suggests that viruses with low entry efficiency, and low affinity for 
CD4 and CCR5 host receptors are still transmitted.  However, viruses with high entry may have 























Chapter 3: Characterization of Envelope function of transmitted/founder viruses circulating in Mbeya and its 
impact on disease progression 




In most cases, HIV transmission is characterized by a genetic bottleneck whereby one or few 
closely related variants establish productive infection (Abrahams et al., 2009; Haaland et al., 
2009; Keele et al., 2008; Nofemela et al., 2011).  T/F variants have been shown to share 
common genotypic and phenotypic characteristics such as R5 tropism, fewer potential N-
glycosylation sites (PNGs) and more compact Envelopes (Chohan et al., 2005; Derdeyn et al., 
2004; Zhang, 1999).  It has also been suggested that availability of target cells in the genital tract 
could play a role in the preferential transmission of certain variants (Hu et al., 2000; Miller et al., 
2005; Ochsenbauer et al., 2012; Salazar-Gonzalez et al., 2009; Zhang, 1999).  Together these 
findings suggest that viral and host factors might act in concert to select specific variants for 
transmission.  The elucidation of the biological characteristics of transmitted variants that impact 
HIV-1 transmission fitness and subsequent pathogenicity is important for the design of vaccines 
effective against these incoming viruses.  
Previous studies have shown that biological properties such as viral replicative fitness are 
determining factors in viral control with variants with low replicative fitness associated with 
long-term non-progression and elite control during chronic (Miura et al., 2009b; Quiñones-
Mateu et al., 2000) and acute infection (Miura et al., 2010).  We and others have also shown that 
infection with transmitted variants carrying known attenuating mutations in Gag was associated 
with lower viral load set point and higher CD4 counts (Chopera et al., 2008; Goepfert et al., 
2008).  A recent study of mother-to-child transmission demonstrated that viruses transmitted 
from mothers with chronic infection to their infants had V1-V5 Envelope regions that conferred 
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Envelope plays a major role in the competitive and adaptive ability of the virus (Rangel et al., 
2003; Travers et al., 2005) and that host cell entry efficiency is a determinant of overall viral 
fitness (Marozsan et al., 2005) and thus disease progression (Lassen et al., 2009).  While there is 
limited information on elucidating the phenotypic properties of transmitted viruses in subtype B 
and C cohorts (Ochsenbauer et al., 2010; Salazar-Gonzalez et al., 2009; Lassen et al., 2009; Ping 
et al., 2013), the identification of the properties of T/F viruses in a genetically diverse setting has 
not been fully explored. This study aimed to characterize T/F viruses representative of different 
HIV-1 subtypes circulating in Mbeya, Tanzania. These Envelopes, cloned from single variant 
transmission events, were characterized in order to elucidate potential biological properties 
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3.2.1 Cohort description 
 
The HIV Superinfection Study (HISIS) high risk cohort from Mbeya, Tanzania recruited 
participants within three months of their previous HIV negative sample (Herbinger et al., 2006; 
Riedner et al., 2006).  Analysis of 212 env sequences from 22 participants (n = 10 sequences per 
participant) generated using single genome amplification (SGA) indicated that sixteen 
participants were infected with a single infectious unit at transmissio  (see Chapter 2) 
(Nofemela et al., 2011). Neighbor-joining trees and HIGHLIGHTER plots 
(http://www.hiv.lanl.gov) of the SGA sequences were used to identify the sequence of the T/F 
virus, and the amplicons identical to the consensus sequence were cloned.  The clones were 
generated as part of the Vaccine Immune Monitoring Consortium, Collaboration for AIDS 
Vaccine Discovery (VIMC – CAVD) (http://www. cavd.org.za) which involves the generation of 
functional clones from different subtypes and diverse geographical regions to assess vaccine-
elicited neutralizing antibodies and to study broadly neutralizing antibodies. 
3.2.2 PCR amplification and cloning of the env gene. 
 
The PCR amplification of the HIV-1 env gene was done using the SGA approach previously 
described (Abrahams et al., 2009; Keele et al., 2006).  The second round PCR reaction was 
repeated using the high fidelity Phusion Hot Start DNA Polymerase (Finnzymes), together with, 
0.2 mM dNTPs (Roche), 4 uM of Env 1A-Rx (5' CAC CGG CTT AGG CAT CTC CTA TAG 
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Volume of 50 μl.  The cycling conditions for this reaction were as follows: denaturing at 94 ºC 
for 5 minutes, 45 cycles of 94 ºC for 30 seconds; 55 ºC for 30 seconds; 72 ºC for 4 minutes, and 
final extension step at 72 ºC for 10 minutes.  The amplicons were gel purified and cloned into the 
mammalian expression vectors pcDNA3.1D/V5-His-TOPO (Invitrogen) or pTarget (Promega, 
US) according to the manufacturer’s instructions.  Functional Envelope clones were selected 
using a 96-well plate format, and the Envelope clones with a RLU that is 2.5 times above 
background were considered to be functional. 
3.2.3 Pseudovirion entry efficiency assays 
 
Pseudoviruses were generated by co-transfection of HEK 293T cells with 2.5 μg env and 5 μg of 
either the subtype B HIV-1 backbone pSG3∆env (gift from L. Morris, NICD) or the subtype C 
backbone pBR264F-Mlu∆env (gift from B. Hahn, UAB) using PolyFect Transfection Reagent 
(QIAGEN). After 48 hours, the viral supernatant (2 ml) was harvested and clarified through a 
0.45 μm filter and stored at -80° C.  Pseudovirus titer was normalized using p24 ELISA 
(Vironostika HIV-1 Antigen microelisa system, Biomerieux, FRA) according to the 
manufacturer’s instructions. TZM-bl cells (1 X 10
4
 cells) were infected in triplicate with 50 
ng/ml p24 of pseudovirus for 48 hours before medium was removed and cells were lysed with 
Bright-Glo buffer (Promega, US).  Luciferase activity [relative light units (RLU)] was measured 
using a Glomax 96 microplate luminometer (Promega, US).  The functional subtype C clone, 
Du151a was used as a positive control (van Harmelen et al., 2001) and included in all 
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Pseudovirion stock generated by the transfection of the pSG3∆env backbone was used as a 
negative control, and the RLU reading of cells only was considered as background signal.  A 
RLU reading of 2.5 times above background was considered a positive infection.  Relative 
infectivity in TZM-bl cells was measured as the % infection relative to Du151a). 
3.2.4 Coreceptor phenotype 
 





 backbone (NIH Aids Reagent Programme). U87 cell lines that express CD4 and 
either CCR5 or CXCR4 coreceptor were infected with 50 ng/ml p24 of virus and luciferase 
activity was measured after 48 hours.  Viruses that were able to infect the U87- CD4 - CCR5 
cells were classified as R5 tropic, and viruses that infected U87 – CD4- CXCR4 were classified 
as X4-tropic.  The Envelope clones QHO (Li et al., 2005), RPI (Cilliers et al., 2005), and Du179 
(Van Harmelen et al., 2001) were obtained from Penny Moore (NICD), and were used as 
positive controls for R5, X4, and dualtropic R5X4 variants, respectively.  A pseudovirion stock 




 backbone was used as a negative control, 
and the RLU reading of wells containing cells only was considered as background signal. 
3.2.5 Pseudovirus entry inhibition assay 
 
TZM-bl cells (1 X 10
4 
cells per well) were infected in triplicate with pseudovirus (50 ng p24) in 
the presence of increasing concentration of TAK779 (0.04 - 400 nM) and T-20 (0.3 μg/ml – 25 
μg/ml) (NIH Aids Reagent Programme), and luciferase activity was measured after 48 hours, and 
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(CA, USA).  Soluble CD4 IC50 was measured as part of the VIMC-CAVD (http://www.cavd.org) 
study and included in this analysis. 
3.2.6 Cell-cell fusion assay 
 
HEK 293T cells (4 x 10
5
) were seeded in 6 well plates overnight, and co- transfected with  3.75 
μg of each individual env plasmid and 3.75 μg of pSVtat72 (NIH AIDS Reagent Programme) for 
48 hours using the PolyFect Transfection Reagent (QIAGEN, US) according to the 
manufacturer’s instructions.  The cell medium was removed and the cells were lifted using 0.04 
% EDTA. The 293T cells (1 X 10
4
 cells per well) were added to TZM-bl cells (1 X 10
4 
cells per 
well) and allowed to incubate at 37 
o
C for 24 hours.  The media (100 μl) was removed from the 
cells, and 100 μl of Bright-Glo buffer (Promega, US) was added.  The plate was incubated for 2 
minutes at room temperature with mild shaking.  After cell lysis, 150 μl was transferred to a Co-
Star black plate, and the plate was read immediately using a Glomax 96 microplate luminometer 
(Promega, US).  The percentage fusion efficiency was measured relative to the reference clone, 
Du151a. 
3.2.6 Pseudovirion infection of Affinofile cells. 
 
Pseudoviruses were generated by co-transfecting HEK 293T cells with 5 μg of env plasmid and 




 backbone (NIH Aids Reagent Programme). 
Pseudovirus-containing cell culture medium was collected after 48 hours, and filtered (0.45 μM) 
before p24 levels were measured (Vironostika HIV-1 Antigen microelisa system, Biomerieux, 
FRA).  The Affinofile cell lines, a generous donation from Benhur Lee (UCLA), were induced 
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Affinofile cells (1 X 10
4 
cells per well) were seeded in 24-well plates, and induced with a 
concentration range of minocyline (0 to 5ng/ml) and ponasterone A (0 to 4 μM) to induce CD4 
and CCR5 expression, respectively.  The cells were collected after 24 hours and washed with 
PBS before staining. The cells were stained with PE anti-human CD4 and PE anti-human CD195 
(CCR5) (BioLegend, US) for 30 minutes at room temperature.  The absolute number of CD4 and 
CCR5 was quantified using the Quantibrite beads (BD Biosciences, US) according to the 
manufacturer’s instructions.  The data acquisition and flow cytometry analysis was done using 
Cellquest and Flowjo software, respectively. 
 Affinofile cells (1 X 10
4 
cells per well) were seeded in a 96-well plate for 48 hours, and were 
induced with minocyline (2.5 – 5 ng/ml) and ponasterone A (2 - 4 μM) for 24 hours.  The cells 
were then infected with 100 ng/ml p24 pseudovirus and infection was determined after 48 hrs 
using luminescence.  Entry efficiency in 293Affinofile cells was determined based on 
luminescence. CCR5 dependence (% infection relative to high CD4/high CCR5) was determined 
using the following equation: RLU (high CD4/low CCR5)/RLU (high CD4/high CCR5) X 100 
(Ping et al., 2012).  
3.2.7 Pseudovirus Envelope Western Blotting  
 
Pseudoviral stocks were generated by co-transfecting HEK 293T cells (2 X 10
6 
cells) with 5 μg 
of cloned Envelope and 10 μg of the subtype B HIV-1 backbone pSG3∆env.  After 48hrs, the 
clarified culture medium was centrifuged at 26 000 rpm for 2 hrs through a 20 % glycerol 
cushion at 4° C in a RW55 rotor (Beckman Coulter, GER) to harvest pseudovirus.  The viral 
pellet was resuspended in PBS for p24 determination and viral quantitation using the Vironostika 
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buffer [40 MM Tri-HCL (pH 6.8), 10 % glycerol, 10 % β mercaptethanol, and 1 % SDS].  The 
equivalent of 1.5ug/ml (for gp120) and 50ng/ml (for 24) p24 pseudoviral lysate was resolved 
using 8 % SDS PAGE before transfer to nitrocellulose membrane.  The primary antibodies 
(sheep anti-gp120 and rabbit ARP 432) raised against gp120 and p24, respectively were obtained 
from the NIH AIDS Reagent Programme.  Primary antibodies for gp120 and p24 were detected 
with horseradish peroxidase-conjugated goat-anti-sheep IgG (Sigma, US) and alkaline 
phosphatase-conjugated goat anti-rabbit IgG (Sigma, US) secondary antibodies respectively.  
The gp120 Western blot was detected using the LumiGlo chemiluminescent substrate (KPL) and 
exposed to X-ray film and the p24 Western Blot was visualised with NCIP/BCIP tablets (Roche, 
GER).  
3.2.8 Statistical analysis 
 
The association of entry efficiency with viral load and fusion capacity was calculated using the 
Spearman correlation test.  These figures were constructed using GaphPad Prism 5 software 
(CA, USA). Classification of the Envelope clones into high and low entry efficiency groups were 
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3. 3 RESULTS 
3.3.1 Cloning of the transmitted/founder (T/F) virus envelope 
 
The env sequences from recently infected participants from the Mbeya region of Tanzania has 
been previously described (see Chapter 2) (Nofemela et al., 2011) and for this study we selected 
ten participants identified as infected with a single variant belonging to either subtype C (n = 6), 
D (n = 1) or recombinant CD (n = 2) or AD (n = 1).  In order to characterize the fitness 
properties of Envelope of the virus that caused clinical infection, we generated functional 
Envelope clones whose sequences were identical to the consensus of SGA-derived sequences.  
These molecular clones were assumed to represent the transmitted/founder (T/F) virus 
responsible for clinical infection.  The T/F Envelope clones characterized in this study were 
generated from samples collected at the first seroconversion visit.  These individuals were 
estimated to be infected for between 14 – 45 days (median = 42.5 days post-infection), and the 
plasma viral loads at the time of sampling ranged from 2 378 to > 750 000 copies/ml (Table 
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>50: Resistant to 50 μg/ml sCD4; Resistant to 400nM TAK779; 25μg/ml T20.  
> 750 001 shows the limit of detection for the Amplicor HIV Monitor assay 
* Participant identification: clone number_transmitted/founder virus_country of origin 








Table 3.1 Description of transmitted/founder Envelope clones from a high risk population of female bar 
workers from Mbeya, Tanzania  
  
    




Subtype  Fiebig 
staging  















390_T/F_TZ  45  C  V  >750 001  R5 2.50  21.28  1.86  
89_T/F_TZ  14  CD  I/II  >750 001  R5 2.20  9.84  1.16  
216_T/F_TZ  14  C  VI  >750 001  R5 >50  125.50  2.41  
605_T/F_TZ  41  AC  V/VI  434 000  R5 7.4  20.32  0.75  
401_T/F_TZ  45  CD  ND  51 500  R5 10.0  60.77  1.35  
234_T/F_TZ  45  C  V/VI  509 000  R5 5.40  101.33  1.43  
569_T/F_TZ  45  C  V/VI  23 800  R5 14.40  42.94  3.30  
346_T/F_TZ  41  C  VI  26 700  R5 1.56  33.63  5.46  
54_T/F_TZ  42  D  VI  28 200  R5 >50  >400  >25  
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3.3.2 Entry efficiency differs between T/F Envelope pseudoviruses 
 
Pseudovirion entry efficiency was compared to a reference clone, Du151a measured in parallel to 
determine a relative fitness score and to control for inter-experimental variation (Gottlieb et al., 
2004; Nofemela et al., 2011).  Pseudovirion entry efficiency was compared using both subtype 
B, (pSG3.1∆env) and subtype C, (pBR264F-Mlu∆env) HIV-1 backbones to determine whether 
subtype differences would impact Envelope function. The relative entry efficiency of the 
pseudoviruses generated using subtype B and the subtype C backbone vectors varied 164 - fold 
and 52 - fold respectively (data not shown).  Furthermore, there was a direct correlation between 
the relative entry efficiency of the pseudoviruses generated using subtype B and subtype C 
backbone vectors (p = 0.0047).  Lastly, subtype C Envelopes did not have enhanced function 
when coupled with a subtype C backbone.  Together these results suggest that the subtype of the 
HIV-1 backbone did not impact the relative entry efficiency of the Envelope clones suggesting 
that subtype specific protein-protein interactions did not influence the assay.  This heterogeneity 
in entry efficiency between Envelopes irrespective of the backbone used, suggests that in the ten 
samples that were analyzed, high Envelope entry efficiency is not a prerequisite for HIV 
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Figure 3.1 Envelope clones of transmitted/founder viruses have a wide range of entry efficiency.  The entry 
efficiency of 10 transmitted/founder env variants, relative to Du151a (positive control) was determined using 
pseudovirions generated with pSG3.1Δenv.  The red and blue bars represent those clones with low and high TZM-bl 
entry efficiency.  Infection was performed in triplicate for each of the variants and this is a combined result of two 
pseudovirus preparations  with the error bars indicating standard deviation.   
 
3.3.3 T/F Entry efficiency is associated with disease progression 
 
In order to investigate the relationship between Envelope entry efficiency of T/F variants and 
viral loads subsequent to transmission in a cohort of women infected with multiple circulating 
subtypes and recombinants, the association between entry efficiency and viral loads at 3 and 12 
months post infection was determined.  The Envelope from T/F variants infecting individuals 
with high viral load at 3 and 12 months post infection had higher entry efficiency compared to 
those variants infecting individuals with low viral loads (p = 0.0022 and p = 0.0347, 
respectively).  The same relationship was observed with pseudoviruses generated using the 
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(data not shown), suggesting that entry efficiency of T/F variants could be a predictor of disease 
outcome (Fig. 3.2).  However, in noted that the viral measurement of >750 001 for three samples 
is somewhat truncated and represented the limit of detection for the assay. While it would be 
ideal to dilute the plasma samples to determine the absolute viral load levels, this  is however  
unlikely to affect the correlation  that was observed . Also, these findings support other previous 
studies that have shown a similar correlation between viral replicative fitness and viral load 







Figure 3.2 The Envelope entry efficiency of T/F variants is associated with viral load.  Pseudovirions were 
generated using the Subtype B backbone pSG3∆env and entry efficiency was measured using TZM-bl cells relative 
to Du151 (% infection).  The association between relative infectivity and viral load at A) 3 and B) 12 months post-
infection was analysed using a Spearman correlation test. 
 
3.3.4 Coreceptor tropism and inhibition kinetics are not associated with entry efficiency of 
TZM-bl cells 
 
CCR5-utilising viruses are preferentially transmitted (Berger et al., 1999) while the development 
of CXCR4 tropism has been linked to increased disease progression (Koot et al., 1993; Sucupira 
P = 0.0022
R = 0.8651
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et al., 2012).  Furthermore, previous studies have demonstrated the role of coreceptor usage in 
HIV-1 replicative fitness (Arie et al., 2005; Quiñones-Mateu et al., 2000).  In order to determine 
whether tropism played a role in the entry efficiency of the T/F variants, U87 cells expressing the 
CD4 receptor as well as either CCR5 or CXCR4 coreceptors were infected with pseudovirus.  
All the Envelope clones were R5 tropic as only U87 - CD4 – CCR5 cells were infected and not 
those expressing CXCR4 (data not shown), suggesting that viral tropism did not contribute to the 
observed differences in entry efficiency of the variants (Table 3. 1).  
In order to examine whether differences in entry efficiency of the T/F variants were due to 
changes in binding affinity to host receptors (Reeves et al., 2002), we determined the IC50 of 
TAK779 (CCR5 antagonist) and T-20 (fusion inhibitor). The sensitivity of the viruses to soluble 
CD4 was also determined. However, this was not used as a measure of binding affinity as a 
number of studies have shown  that soluble CD4 can either enhance (Allan et al., 1990; Allan et 
al., 1991; Clapham et al., 1992) or inhibit HIV infection (Deen et al., 1988; Fisher et al., 1988; 
Hussey et al., 1988; Smith et al., 1987; Traunecker et al., 1988).  There was variation in 
sensitivity of the Envelope clones to sCD4 (IC50 median = 6.4 μg/ml; range = 1.6 – 16.4 μg/ml), 
TAK779 (IC50 median = 33.63 nM; range = 8.18 – 126.50 μM), and T-20 (IC50 median = 1.64 
μg/ml; range = 1.15 – 5.45 μg/ml).  One pseudovirus (clone 398) was resistant to T-20, and one 
(clone 54) was resistant to both TAK779 and T-20 and these clones were excluded from the 
statistical analysis.  There was no significant correlation between entry efficiency of TZM-bl 
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A                                                           B    
P = 0.2788
R = -0.3769
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Figure 3.3  Association of Envelope entry efficiency with sensitivity to entry inhibitors  IC50 of entry inhibitors: 
sCD4 (A), TAK779 (B) and T-20 (C) was determined for each Envelope clone and its association with the 
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3.3.5 Cell surface CD4 is critical for successful host cell entry of transmitted viruses  
 
CD4 and CCR5 density is an important determinant of HIV infectivity (Heredia et al., 2007; 
Kabat et al.,  1994; Lee et al., 1999; Parker et al., 2012; Platt et al., 1998; Reynes et al., 2000; 
Walter et al., 2005)  and while the number of CD4 molecules on the surface of peripheral T cells 
remains constant (Poncelet et al., 1991), the levels of CCR5 receptors differs between 
individuals and is thought to play a more critical role (Lee et al., 1999; Reynes et al., 2000).  It is 
possible that high expression levels of CCR5 by TZM-bl cells may mask subtle differences in the 
ability of T/F Envelope clones to mediate entry and membrane fusion as high CCR5 density has 
been shown to hasten membrane fusion kinetics (Heredia et al., 2007; Reeves et al., 2002) and 
infectivity of cells with high CCR5 were shown to be indep ndent of CD4 levels (Platt et al., 
1998).  Therefore, by changing the level of receptors at the cell surface we aimed to determine 
the ability of T/F viruses to infect cells with low receptor levels and also to distinguish those 
envelope clones with high receptor affinity from those with low affinity for CD4 and /or CCR5.  
 HEK 293 Affinofile cells were induced to express different levels of surface CD4 and CCR5 to 
generate cells with: 1) high CD4 (146 397 molecules/cell), low CCR5 (2 566 molecules/cell); 2) 
low CD4 (2 397 molecules/cell), high CCR5 (428 032 molecules/cell; and 3) high CD4 and high 
CCR5 levels (146 397 and 428 032 molecules/cell respectively).   
All the T/F Envelope pseudovirions were able to infect cells with high CD4 and high CCR5 
levels and the Envelope clones with low entry efficiency in TZM-bl cells also had low entry 
efficiency in Affinofile cells.  All of the Envelope pseudovirions were able to infect cells when 
CCR5 levels were lowered to 2 566 molecules/cell although infection dropped by 4 to 5-fold (% 
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dependency on high levels of CD4 for entry (Fig 3.4 A). This supports previous findings of Platt 
et al., (1998) which showed that trace amounts of CCR5 could support HIV infection if CD4 
numbers were high.  However, when CD4 receptor levels were lowered (3 401 molecules/cell) 
and CCR5 numbers were high (428 032 CCR5 molecules/cell), the virus mediated entry very 
poorly with nearly 100 - fold decrease compared to cells with high CD4 and high CCR5 levels   




 range = 0.003 – 0.5%; median = 0.08%) (Fig. 3.4B). 
This suggests that the Envelope pseudovirions in this study require a minimum level of CD4 
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Figure 3. 4 Pseudovirion entry efficiency in dual inducible HEK293 Affinofile cells at (A) High CD4 and Low 





. The grey bars indicate the pseudoviruses with low entry efficiency and the black bars are the 
pseudoviruses with high entry efficiency as previously described. The level of entry efficiency was measured in 
RLU. This figure is a result of two assays using two pseudovirus preparations, and the error bars represents the 
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3.3.6 CD4 and CCR5 binding affinity a determinant of entry under limiting 
receptor/coreceptor levels 
 
As only three out of five Envelope clones with high entry efficiency were able to infect cells 
with low CD4 levels, and there was a relative 4 - 5 fold drop in entry efficiency for all clones 
when CCR5 levels were lowered, we wanted to determine whether binding affinity to either CD4 
or CCR5 played a role in this dependency on high CCR5 receptor numbers.  We therefore tested 
the relationship between the IC50 values obtained using soluble CD4, TAK779 and T-20 and 
CCR5 dependence (which is calculated as % infection relative to high CD4/ high CCR5 levels) 
(Ping et al., 2012).  The lower the percentage value, the higher the dependency on CCR5 levels 
and the greater the difficulty in entering cells with low CCR5 density.  In cells with high CD4 
levels and low CCR5 levels there was a positive correlation between CCR5 dependence and the 
IC50 measurements of soluble CD4 and TAK779 (p = 0.0438; p = 0.0138, respectively) (Fig. 3.6 
A, B), suggesting that the ability to enter cells with low CCR5 levels was determined by binding 
affinity to CD4 and CCR5.  The correlation between soluble CD4 IC50 measurements and 
coreceptor dependence became more significant when the CD4 levels were lowered to 69 988 
molecule/cell (p = 0.0234) whereas significance was lost with TAK779 affinity (p = 0.1938) 
(Fig. 3.6 D, E).  The ease with which pseudovirions are able to enter cells with low CCR5 levels 
is thus directly related to Envelope binding affinity for CD4 and CCR5 and influenced by the 
relative abundance of the receptor and coreceptor on the host cell.  Overall, this also suggests 
that binding affinity to CD4 and CCR5 is a determining factor in entry efficiency, as T/F clones, 
classified as having high efficiency in TZM-bl cells, infected Affinofile cells with limiting 
receptor levels better than the low TZM-bl entry efficiency group (Fig. 3.5).  Finally, there was 
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levels tested (p = 0.2992, p = 0.8401, respectively) (Fig. 3.6 C, F) suggesting that membrane 
fusion kinetics was not a determinant of entry efficiency under limiting host receptor conditions. 
 A                                            B                                                C 
P = 0.0438
r = 0.6626
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Figure 3.6 Infection of cells with low CCR5 levels is associated with binding affinity for CD4 and CCR5. 
Pseudovirion entry was determined of Affinofile cells induced to express different levels of CD4: (A, B and C) 146 
397 molecules/cell and (D, E and F) 69 988 molecule/cell with constant low levels of CCR5 (2 566 molecules/cell). 
Spearman correlation was carried out to determine the relationship between CCR5 dependence and soluble CD4, 
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3.3.7 Fusion capacity is not associated with entry efficiency 
 
As both TZM-bl and Affinofile entry under both high and low host receptor levels was not 
associated with sensitivity to T - 20, a cell-cell fusion assay was performed to determine whether 
this step contributed to differences in entry efficiency.  HEK 293T cells, co-expressing Envelope 
and Tat, were added to TZM-bl cells which stably express the LTR - luciferase reporter gene. 
Luciferase activity was measured after 24 hours as fusion between the two cells would enable the 
transfer of Tat to TZM-bl cells resulting in luciferase expression.  Although there was no 
statistically significant association between fusion and entry efficiency (p = 0.8916) (Fig. 3.7B), 
Envelope clones classified with high entry efficiency had relatively high fusion capacity (71 – 
138 % relative to Du151a), and three out of the five clones with low entry efficiency had lower 
fusion capacity (43 – 53 % relative to Du151a) (Fig. 3.7A).  However,   two of the clones (54 
and 569) with low entry efficiency had high fusion capacity (relative fusogenicity = 240 % and 
140 % respectively) suggesting, at least with these clones, that fusion was not the major 
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Figure 3.7 Cell-cell fusion capacity is not always associated with TZM-bl entry efficiency.(A) Envelope fusion 
capacity of the transmitted variants was determined by using a cell-cell fusion assay and (B) the association between 
entry efficiency and fusion capacity was determined using a Spearman Correlation test.  The blue bars indicate the 
viruses with high entry efficiency and the red bars are the viruses with low entry efficiency. 
 
 
3.3.8 Envelope incorporation into pseudovirion particles affects entry efficiency 
 
The number of functional Envelope trimers incorporated into the viral particle (Moore et al., 
2006), as well as correct processing of the immature protein (gp160) into gp120 and gp41, 
impacts HIV-1 infection (Bachrach et al., 2005; Blay et al., 2007; Provine et al., 2009).  SDS 
page was used to characterize Env processing and to determine the amount of protein that is 
required to ensure the visibility of the protein on the blotting membrane.   This is done by means 
of a semi quantitative method which involves the serial dilution of the pseudovirion samples to 
determine the p24 concentration that provides a linear range of detection.  In order to determine 
whether entry efficiency was linked to Envelope incorporation and processing, pseudovirion 
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SDS PAGE and Western blotting against gp120 and p24.  Equivalent pseudoviral particles, as 
determined by p24 concentration were loaded per lane.  The Western blot showed that the 
Envelope pseudoviruses with the highest levels of entry efficiency (89, 216, 390) had high levels 
of both gp160 and gp120 incorporation.  The Envelope pseudoviruses with the lowest entry 
efficiency (54, 398, and 569) had a single, band which was difficult to identify as either gp160 or 
gp120 due to the heterogeneity in molecular weight of the Envelope clones, however the low 
intensity of the band suggested poor incorporation compared to those with high entry efficiency.  
However, pseudoviruses 234 and 346 had good gp120 incorporation despite having low entry 
efficiency, and pseudovirus 605 showed low or very little processing despite having high entry 
efficiency (Figure 3.8).  Overall, these differences suggest heterogeneity in the level of gp120 
incorporation into the virus which may contribute to high entry efficiency of some T/F variants.  
 
 
Figure 3.8 Gp120 pseudovirion incorporation varies between Envelope clones.  Pseudovirions were generated in 
HEK 293T cells, and culture supernatants were layered over 20% glycerol and ultracentrifuged at 26 000 RPM for 2 
hours.  The pelleted viruses were lysed and 1.5 ug/ml and 50ng/ml of p24 was loaded per lane for gp120 and p24 
respectively.  The Envelope clones highlighted with an asterisk are those with high entry efficiency in TZM-bl cells 
Negative control (-ve) comprises viral particles without env and the positive control is HIV-1 gp120 CM cat #2968 
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The genetic bottleneck during HIV heterosexual transmission selects for variants that  almost 
exclusively use CCR5 receptors and carry more compact Envelope with fewer potential N-
glycosylation sites (Abrahams et al., 2009; Haaland et al., 2009; Keele et al., 2008; Zhang, 
1999), suggesting that mucosal factors select Envelope variants enriched with specific functional 
attributes.   Although a few studies have shown a link between Envelope function and HIV 
replicative fitness (Kong et al., 2008; Rangel et al., 2003) and replicative fitness and disease 
progression (Miura et al., 2010; Quiñones-Mateu et al., 2000), only one study on subtype B 
infected elite suppressors demonstrated a link between Envelope function and disease 
progression (Lassen et al., 2009).  The study by Lassen et al., (2009) showed that elite 
suppressors had significantly lower Env entry efficiency than chronic progressors.  In this study 
we report on a study of high-risk women from Tanzania, recruited soon after infection, and show 
that the entry efficiency of multiple subtype and recombinant T/F Envelope pseudoviruses was 
positively correlated with viral loads at 3 months and 12 months post-infection. These findings 
support the findings by Lassen et al., (2009), which show that low viral loads observed in elite 
suppressors was associated with low Env entry efficiency.  Furthermore, we find that the T/F 
Envelopes clones exhibited large differences in entry efficiency that was not associated with a 
specific subtype, and that this together with the heterogeneity in dependency on CCR5 and CD4 
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Due to the relationship between Envelope function in TZM-bl cells and viral loads, we wanted to 
identify the underlying biological factors(s) driving Envelope entry efficiency and thus 
potentially, replication fitness. As HIV replication fitness may be influenced by the level of CD4 
and CCR5 at the surface of T cells (Alexander et al., 2010), we investigated the effect of limiting 
host receptor levels on entry efficiency using Affinofile cells induced to express different levels 
of CD4 and CCR5.  There was a positive correlation of the relative entry efficiency of the 
Envelope clones between TZM-bl cell and Affinofile cells at high levels of CD4 and CCR5, 
however the absolute level of entry efficiency decreased by 4 -5 fold when the CCR5 levels were 
lowered and 100 - fold when the CD4 levels were decreased.  Only three viruses, from the high 
TZM-bl entry efficiency group, were able to infect cells with low CD4 levels, despite high CCR5 
levels. This suggests that these viruses are dependent on a specific number of CD4 molecules per 
cell and thus unlikely to be macrophage tropic similar to recent studies on subtype B and C 
viruses (Ochsenbauer et al., 2012; Salazar-Gonzalez et al., 2009).  The dependency on CCR5 
density correlated significantly with sensitivity to CD4 and CCR5 inhibitors suggesting that 
pseudoviruses with high affinity for CCR5 were able to infect cells with low CCR5 density. 
Furthermore, the large variation of dependence on high CCR5 levels between the clones, 
suggests that the extensive variability of host CCR5 density could influence selection during 
transmission.  
As previous studies have shown that high levels of surface Envelope expression result in 
increased infectivity (Bachrach et al., 2005; Provine et al., 2009), we investigated whether the 
entry efficiency of the T/F Envelope clones is due to enhanced Envelope incorporation.  This 
study found that incorporation/processing of Envelope into virions may impact entry efficiency 
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other viruses. However, the relationship between Envelope incorporation/cleavage/processing 
and entry efficiency was not consistent for all the clones, suggesting that other factors may be 
playing a role in the entry efficiency of the T/F viruses. A recent study by Parrish et al (2013) 
found that T/F are more infectious than viruses at chronic infection, and this was partly due to 
the presence of Envelope particles on the surface, which suggests that Envelope 
incorporation/processing  may play a role in entry efficiency.  In terms of cell-cell fusion assay, 
despite some viruses with high entry efficiency having high cell-cell fusion capacity, there was 
no correlation between entry efficiency and cell-cell fusion.  This discrepancy could be due to 
the two assays measuring different parameters, with the pseudovirus assay being dependent on 
Envelope incorporation into viral particles, and the cell-cell fusion assay reliant on Envelope 
expression on the surface of cells.  Clone 54, which had low entry efficiency and the highest cell-
cell fusion capacity, illustrates this phenomenon. Clone 54 was resistant to sCD4, TAK779 and 
T20 and is therefore likely to have high affinity for CCR5. Reeves et al., (2002) demonstrated 
that increased coreceptor affinity resulted in faster fusion kinetics which may explain the high 
fusion capacity of clone 54.  However, its incorporation into viral particles was very poor which 
would lower its ability to mediate entry of TZM-bl cells.  
Finally, this study investigated the entry efficiency of T/F Envelope clones from 10 participants, 
six infected with subtype C, three infected with recombinant forms (CD, AC and AD) and one 
with a subtype D variant.  Phenotypic coreceptor tropism results indicated that all were R5 tropic 
even though subtype D variants are more likely to utilize CXCR4 (Huang et al., 2007).  There 
was no apparent association between entry efficiency, inhibitor sensitivity, receptor dependence, 
fusion capacity or Envelope incorporation and HIV subtype or recombinant form.   However, 
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(Chohan et al., 2005; Derdeyn et al., 2004; Frost et al., 2005a), further studies on non-subtype B 
and subtype C T/F variants might provide important insights into the mechanism of HIV 
transmission.   
In conclusion, this study has shown that Envelopes of T/F variants infecting participants with 
high viral loads had higher entry efficiency compared to those with low viral loads.  This 
association was determined at viral set point (12 months), which suggests that entry efficiency of 
transmitted viruses could influence disease outcome.  The viruses were dependent on high levels 
of CD4 for entry, with many of them unable to infect cells with low CD4 density despite high 
levels of CCR5.  Therefore, T/F variants from multiple subtypes and recombinant forms are 
unlikely to be macrophage tropic, corroborating earlier subtype B and subtype C studies.  The 
phenotypic properties of the viruses were also highly heterogeneous, similar to a previous study 
comparing acute infection subtype B Envelope clones from progressors to those of elite 
suppressors, suggesting that, irrespective of subtype, the genetic bottleneck does not select for 
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As studies have shown discrepancies between pseudoviruses and infectious molecular clones, we 
were interested in characterizing env expressed in chimeric infectious molecular clones (IMCs).  
The Envelope clones were shuttled into a NL4-3 backbone using a yeast gap repair method to 
generate recombinant viruses, and their replication was measured in TZM-bl, PBMCs and 
monocyte-derived macrophages.  In TZM-bl cells, the majority of recombinant viruses (80%) 
showed similar entry efficiency profiles to those in the pseudovirion system.  The replication 
capacity of the recombinant viruses in PBMCs varied between donors, however the recombinant 
viruses replicated much more efficiently in T lymphocytes than in monocyte-derived 
macrophages.  Although the pseudovirion assays showed that the higher replication kinetics in 
vitro was associated with high viral loads in vivo, due to host to host variation we could not 
confirm this finding in PBMCs.  The preferential replication in T-cells is in agreement with our 
results which showed the inability of pseudovirions to infect Affinofile cells induced to express 
low levels of CD4 receptor, and together these results support published studies that T/F viruses, 
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A number of investigators have used the pseudovirus based assay to measure the Envelope 
phenotypic properties of viruses.  While these assays are highly reproducible and are high 
throughput, they use cell lines and can only measure a single cycle of infection.  Therefore, in 
order to circumvent this, it is important to use a system that measures replication fitness over 
multiple rounds of infection, and one that resembles what is likely to be taking place in vivo.  
One approach involves the construction of chimeric infectious molecular clones containing the 
env gene of interest in the context of a full HIV-1 proviral genome backbone (Etemad et al., 
2009; Provine et al., 2009), and measuring replication in peripheral blood mononuclear cells 
(PBMCs) (Arie et al., 2005; Ochsenbauer et al., 2012; Quiñones-Mateu et al., 2000; Salazar-
Gonzalez et al., 2009).  Our previous findings using the pseudovirus (PSV) system has shown 
certain properties in Envelope are important for enhanced entry efficiency during acute infection, 
and could possibly predict disease outcome (see See Chapter 2).  Therefore, in order to validate 
these findings under biologically relevant conditions, this study aimed to determine the 
efficiency at which these viruses replicated in different target cells including TZM-bl, PBMCs 
and monocyte-derived macrophages.  
In order to fulfill the objective of the study, replication competent recombinant viruses carrying 
Envelope clones from transmitted/founder (T/F) viruses (see Chapter 2) were generated using 
the NL4-3 backbone and the yeast gap repair system.  This process occurs by means of 
homologous recombination in yeast cells.  Homologous recombination is a natural mechanism 
that is used by yeasts to repair its chromosomal DNA. It uses regions of homology between the 
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advantages over the bacterial cloning in that it is very efficient, precise, and also uses negative 
selection markers that ensure the insertion of the env gene in the correct orientation (Baudin et 
al., 1993; Lorenz et al., 1995; Sikorski & Hieter, 1989).  Also, this method does not require 
restriction enzyme digestions, gel purifications, in vitro ligations, and screening of the inserts in 
order to produce an infectious full-length proviral DNA vectors (Dudley et al., 2009).   The 
replication capacity of the recombinant viruses was subsequently evaluated in PBMCs and 
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4.2 MATERIALS AND METHODS 
 
4.2.1 Amplification of the HIV-1 env gene by Single Genome Amplification 
Refer to Chapter 2.2.2.2  
 
4.2.2 DNA gel isolation and purification 
 
The gel purification was done using the QIAquick Gel Extraction Kit (QIAGEN, US) according 
to the manufacturer’s instructions. 
4.2.3 Plasmids  
 
The subtype B backbone CMV –PBS-LTR-NL4-3∆gp160 URA) was used for the yeast gap 
repair method.  The 5’ LTR has been replaced with a CMV promoter in order to prevent 
recombination of the entire HIV genome and thus expression of the HIV genes is under the 
control of the CMV promoter.  The env gene is replaced by the (URA3) gene, which encodes the 
orotidine – 5’ phosphate decarboxylase protein which is involved in the biosynthesis of uracil.  
The plasmid also contains the beta – isopropylmalate dehydrogenase gene for the biosynthesis of 
leucine (LEU), an autonomously replicating sequence (ARSH4), and the yeast centromere 
sequence (CEN6), which all enables the recombinant plasmid to be cultured in yeast cells.  The 
CMV NL4-3 Gag4 was used as a helper plasmid.  A subtype B env-expressing plasmid derived 
from NL4-3 (CMV NL4-3 GT) was used as a positive control in the TZM-bl infections.  These 
plasmids were provided by Dr. Manish Sagar, Brigham and Women’s Hospital, Harvard Medical 
School, US.   The subtype B virus NL4-3 was used as a positive control for PBMC infection, and 
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4.2.4 Yeast gap-repair homologous recombination 
 
The yeast competent cells were initially thawed at room temperature. The sonicated salmon 
sperm DNA (Agilec Technologies, US) was heated at 95 °C and put on ice for at least 2 minutes.  
The vials of 100 µl of yeast cells (Saccharomyces cerevisiae Hanson (MYA-906), MAT α ade6 
can1 his3 leu2 trpl URA3) were centrifuged at 13 000 rpm for 30 seconds, and the supernatant 
was discarded.   The amplified DNA (1 µg/ul) and vector (CMV –PBS-LTR-NL4-3∆gp160 
URA) (200 ng/µl) were added to the cells, and distilled water was added to a final volume of 74 
µl.  The yeast cells were gently resuspended, and 10 µl of 10 mg/ml sonicated salmon sperm 
DNA, 36 µl of 1M Lithium Acetate (see Appendix D), and 240 µl of 50% sterile polyethylene 
glycol (PEG) (Sigma-Aldrich, US) (see Appendix D) was added to the cells and mixed by 
pipetting gently several times. The tubes were then initially incubated at 30 °C for 30 minutes, 
with subsequent heat shocking at 42 °C for 15 minutes.  The tubes were then centrifuged at 13 
000 rpm for 30 seconds.  The supernatant was discarded, and the pelleted cells were resuspended 
in 100 μl of 1 X TE buffer.  The cells were then plated on (C – Leu/5- FOA) selective plates (see 
Appendix D) and incubated at 30 °C for 3 - 4 days. The mixture of yeast cells with only the 
vector was used as a negative control.  The construction of recombinant NL4-3 viruses using the 
yeast-gap repair method was done in Dr Manish Sagar’s Laboratory at Brigham and Women’s 
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4.2.5 Yeast DNA plasmid rescue and transformation 
 
Two colonies were picked from each plate and grown in 2 ml of C – Leu culture media (see 
Appendix D) at 30 °C with shaking overnight.  The overnight cultures were used to extract 
plasmid DNA from the yeast cells. 
The overnight culture was transferred to a sterile 2 ml tube and the culture was centrifuged at 13 
000 rpm for 5 minutes, after which the supernatant was discarded.   The yeast pellets were 
resuspended in 200 μl of Yeast Lysis Buffer (see Appendix D).  The acid washed baked beads 
(Sigma-Aldrich, US) (200 μl) were added together with 200 µl of phenol/chloroform (Sigma-
Aldrich, US).  The mixture was vortexed for 2 minutes, and then centrifuged at 13 000 rpm for a 
further 2 minutes.  The top (aqueous) layer was removed and transferred to a new sterile 1.5 ml 
tube.  The volume of the fluid was determined and 1/10 volume of 3 M Sodium Acetate (see 
Appendix C) was added to the fluid, after which two volumes of 100 % ethanol was then added.  
The mixture was placed on ice for 5 minutes and then centrifuged at 13 000 rpm for 10 minutes.  
The supernatant was discarded and 100 µl of 70 % ethanol was added to the pellet. The tubes 
were again centrifuged at 13 000 rpm for 5 minutes.  The supernatant was discarded, and the 
pellet was air dried for 5 minutes and resuspension in 100 µl of distilled water. 
4.2.6 Transformation of yeast plasmids into competent cells 
 
The plasmid (2 µl) was added to a 50 µl vial of TOP 10® electrocompetent cells and transferred 
to electroporation curvettes (Fisher Scientific, US), and were then electroporated at 1.80 V using 
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was added to the cells, and incubated at 30 °C with shaking for 1 hour. The cells were then 
plated onto LB plates (see Appendix D) and stored at 30 °C overnight. 
One colony was picked from each plate and cultured overnight at 30 °C in 5 ml of LB broth (see 
Appendix D) containing 100 μg/ml ampicillin.  
 
4. 2.7 Plasmid DNA extraction 
 
The overnight culture (4 ml) was used to extract plasmid DNA from the bacterial cells using the 
QIAprep Spin Miniprep Kit (QIAGEN, US), and this was done according to the manufacturer’s 
instructions.  
4. 2.8 Screening of recombinant plasmids by PCR amplification and sequencing 
The recombinant plasmids were screened for the presence of env by PCR using Env-IF and Env- 
IR.  The plasmids were also screened by DNA sequencing using primers Env- OF (5’ GGC TTA 
GGC ATC TCC TAT GGC AGG AAG AA 3’) and Env- OR (5’ TAG CCC TTC CAG TCC 
CCC CCT TTT CTT TTA 3’). 
4. 2.9 Viral production by DNA transfection 
 
The replication competent viruses were generated by co-transfection of HEK 293T cells with 1 
µg recombinant NL4-3 containing the transmitted env and 1 µg of the helper plasmid CMV 
NL4-3 Gag4 using Fugene 6 Transfection Reagent (Roche, GER).  As a positive control, 1µg of 
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NL4-3 Gag4 helper plasmid.  After 48 hours, the viral supernatant (2 ml) was harvested and 
clarified through a 0.45 µm filter and stored at - 80 °C.   
4. 2.10 Viral RLU titration 
 
DMEM medium (100 µl) was added to all the wells of 96 well costar plates. The viral samples 
(100 µl) were added in triplicate onto the plates, and up to four serial dilutions were made for 
each virus. TZM-bl cells (100 µl) (1 X 10
4 
cells per well of media) was added to the plates and 
incubated at 37 °C, 5 % CO2 for 48 hours. 
After 48 hours, the media was removed from the plates and the cells were washed with 1 X PBS. 
The PBS was removed and 20 µl of the Tropix® Lysis Solution (Applied Biosystems, US) was 
added to each well and left at room temperature for 10 minutes.   A 1:100 dilution of the 
Tropix® Galacton-Plus substrate solution was made using the Tropix® Galacto Reaction Buffer 
diluent and 70 µl was added to the plates.  The plates were left on the shaker at room temperature 
for 1 hour.   The Tropix® Accelerator II (100 µl) (Applied Biosystems, US) was added and then 
plates were read using Fluostar Optima (BMG Labtech, US) luminometer. 
 
4. 2.11 Measuring entry efficiency of recombinant NL-4 viruses 
 
The entry efficiency was measured using the method used in the pseudovirion assay (See 
Chapter 2).  The recombinant NL4-3 viruses were generated by transfecting with NL4-3 CMV 
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4.2.12 Replication of recombinant viruses in PBMCs and monocyte-derived macrophages 
 
4.2.12.1 PBMC isolation from blood 
 
The lymphocytes and macrophages were isolated from blood obtained from donors at the 
Massachusetts General Hospital using Ficoll-gradient centrifugation method (see Appendix C).  
The lymphocytes were counted and stimulated with complete RPMI containing PHA and IL-2 
for 24 - 48 hours, and subsequently maintained using RPMI containing fetal bovine serum, 
penicillin-streptomycin, L-glutamine, and HEPES (see Appendix D).  
 
4.2.12.2 Viral expansion in activated lymphocytes 
 
The recombinant viruses were expanded in lymphocytes in order to generate high titers. The 
activated lymphocytes (2 X 10
6 
cells) were transferred to a sterile 15 ml tube, and centrifuged at 
2500 rpm for 10 minutes.  The supernatant was removed and the cells were resuspended with 
500 µl of 293T cell supernatant and 50 µl of 1:100 diluted DEAE dextran and mixed by 
vortexing.  The mixture of cells and virus were incubated for 2 hours at 37 °C, 5 % CO2 for 2 
hours. 
The cells were centrifuged at 2500 rpm for 10 minutes.  The supernatant was discarded and the 
cells were washed with 1X PBS. The washing step was repeated up to four times.  The infected 
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flasks.  The flasks were placed vertically and incubated at 37 °C, 5 % CO2 and the virus was 
collected on Day 4 and 7. 
During every virus collection, the cells were centrifuged at 2500 rpm for 10 minutes. The 
supernatant was removed and aliquoted in cryovials and frozen at - 80 °C.  The cells were then 
resuspended in fresh RPMI containing IL-2 and transferred to the flasks and incubated at 37 °C, 
5 % CO2 for further culturing. 
4.2.12.3 Viral titration using B-gal staining method 
 
The TZM-bl cells (2 X 10
6
 cells per plate) were seeded in 48 well plates overnight. A 1:10 
dilution of each virus was initially done, followed by a further three 1:10 serial dilutions, and the 
volume was made up to 200 µl per dilution.  The media was removed from the TZM-bl cell 
plates, and 50 µl was added in triplicate for each dilution.  The TZM-bl cells were placed in the 
37 °C incubator for 2 hours, and 500 µl of DMEM was added to the cells. The plates were 
incubated at 37 °C, 5 % CO2 for 48 hours. 
After 48 hours, the media was removed and the cells were washed with 1X PBS. The fixing 
solution (see Appendix D) was added to the TZM-bl cells for 5 minutes.  The fixing solution 
was removed and 200 µl of the staining solution (see Appendix D) was added to the cells.  The 
plates were covered in aluminum foil and placed at 37 °C for 2 hours.  The number of infectious 
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4. 2.12.4 Infection of activated lymphocytes by recombinant viruses 
 
Activated lymphocytes and macrophages (10 X 10
6
 cells/ ml) were transferred to a sterile 15 ml 
tube, and centrifuged at 2500 rpm for 10 minutes.  The supernatant was removed and the cells 
were resuspended with 500 IP of 500 µl total volume of virus and 50 µl of DEAE dextran and 
mixed by vortexing.  The mixture of cells and virus were incubated for 2 hours at 37 °C, 5 % 
CO2 for 2 hours. The cells were thereafter centrifuged at 2500 rpm for 10 minutes.  The 
supernatant was discarded and washed with 1X PBS.  The washing step was repeated up to four 
times.  The infected cells were resuspended in 1 ml of RPMI containing IL-2 and were 
transferred to T-25 tissue culture flasks.  The flasks were placed vertically and incubated at 37 
°C, 5 % CO2 and the virus was collected on Days 4, 7, 10, and 14 days post infection. 
During every virus collection, 500 µl of the cells were removed and placed in a 2 ml tube, and 
centrifuged at 2500 rpm for 10 minutes.  The supernatant was removed and aliquoted in 
cryovials and frozen at -80 °C.  Fresh RPMI with IL-2 (500 µl) was added to the plates and 
incubated at 37 °C, 5 % CO2 for further culturing.  
4.2.12.5 Infection of viruses in activated macrophages 
 
The activated macrophages (1 X 10
6
 cells/ml) were seeded in a 24 well plate after 7 days of 
activation.  The medium was removed and the virus (5000 IP in 500 µl) was added to the cells, 
and incubated at 37 °C overnight.  The media was removed from the cells and washed with 1X 
PBS four times, and replaced with fresh macrophage media (see Appendix D) for further 
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During every virus collection, 500 µl of the cells were removed and placed in a 2 ml tube, and 
centrifuged at 2500 rpm for 10 minutes.  The supernatant was removed and aliquoted in 
cryovials and frozen at - 80 °C.  Fresh macrophage media (500 µl) was added to the plates and 
incubated at 37 °C, 5 % CO2 for further culturing.  
4.2.13.6 Measuring replication using an in-house p24 ELISA  
 
Flat bottomed 96 well plates (Nunc) were first coated with 100 µl of coating antibody (4 µl of 
HIV-Ig (50 mg/ml) per 10.5 ml of PBS and then add 100 µl per well).   HIV-Ig is from NIH 
Catalog # 3957, and incubated at 37 °C overnight.   The plates were washed by adding 300 µl of 
1 X PBS (see Appendix D) to each well.  The washing step was done up to six times. The plates 
were then blocked by adding 200 µl of blocking solution (see Appendix D), and incubated at 37 
°C for 2 hours.  The plates were washed using p24 Washing Solution (see Appendix D) using 
Labsystem Wellwash 4 Mk2 plate washer (Fisher Scientific, US), after which the 100 µl of the 
standards and the test samples were added to the plates.  The p24 protein standard (Perkin Elmer) 
was used as the standard, with a starting concentration of 16 ng/ml that underwent two-fold serial 
dilutions to 0.25 ng/ml.  The test samples were added, both undiluted and at a 1:10 dilution for 
each sample to a final volume of 300 µl.  The sample diluent (see Appendix D) was used to 
make up the dilution of the standards and the test samples.  The plates were incubated at 37 °C 
for 2 hours.  The plates were washed again six times with washing solution.   A 1:10 dilution of 
the primary antibody (mouse anti-p24 hybridoma 183 Clone H12-5C) (100 µl) was added to the 
plates, and were incubated at 37 °C for 1 hour.  The plates were washed again with washing 
solution as outlined above.  A 1:70 000 dilution of the secondary antibody (goat anti-mouse 
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plates were then incubated at 37 °C for 1 hour.  The plates were washed again six times with 
washing solution, and 100 µl of detection solution (see Appendix D) was added and before 
incubation in the dark for 30 minutes.  The reaction was stopped by adding 50 µl of 2 M/4 N 
H2SO4, and the plates were read immediately at a wavelength of 490 nm and 490/650 nm using 
the Vmax Kinetic Microplate Reader (Molecular Devices, CA, US). 
The p24 levels were also measured using the Alliance® HIV-1 p24 ELISA Kit (PerkinElmer, 
Waltham MA, US) according to the manufacturer’s instructions.  This kit was used to measure 
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To directly compare the results obtained in the pseudovirus assay to virus replication using the 
IMCs, we used the transmitted/founder Envelope clones (see Chapter 3) to generate 10 env 
chimeric NL4-3 viruses representative of subtype C (n = 6), subtype D (n = 1), and AC (n = 1), 
CD (n = 2) recombinants (Table 4.1).  The env gene was amplified from the plasmid before 
being shuttled into a subtype B backbone CMV –PBS-LTR-NL4-3∆gp160 URA using the yeast 
gap repair recombinant method.  The backbone contains the URA3 gene in place of the env gene, 
and contains 40 nucleotide sequences in both the 5’ and 3’ region that are homologous to the 
HIV-1 env target gene and a ‘gap’ after enzyme digestion with PacI.   This allows for the 
replacement of URA3 gene with the target env gene. After the transformation of the yeast cells,  
the recombinant plasmid was selected on plates containing CMM – Leucine + 5 – flouro – 1, 2, 
3, 6 – tetrahydro – 2, 6 – dioxo – 4 – pyrimidine carboxylic acid (FOA) (which is toxic to the 
yeast cells expressing URA3), thus allowing the growth of the yeast cells that contain the 
recombinant plasmid.   In order to confirm the presence of the correct insert in the correct 
orientation, the plasmid was sequenced using the Env - IF and Env – IR primers, which are 
located on either side of the env gene.  The plasmid was extracted from the yeast and shuttled 
into E.coli to produce many copies of the plasmid.  The plasmids were thereafter transfected into 
293T cells to generate the recombinant NL4-3 viruses.  The titers and levels of entry efficiency 
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4.3.1 Infection of the recombinant viruses in TZM-bl cells 
 
In order to determine whether the recombinant viruses displayed similar infectivity in TZM-bl 
cells compared to pseudovirus restricted to a single round of infection, TZM-bl cells were 
infected with the equivalent of 50 ng/ml p24  replication competent viruses, and infection was 
measured after 48 hours using luminescence.   Of the five viruses classified as having high entry 
efficiency using the pseudovirion assay, four also had high infectivity in the IMC assay, with the 
fifth recombinant virus carrying clone 390 (recNL4-3_390) having low infectivity.  Similarly of 
five viruses classified as low entry efficiency using the pseudovirion assay, four has low 
infectivity in the IMC assay except for one virus (recNL4-3_234), with had high infectivity in 
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Figure 4.1 Comparing the infectivity of the recombinant viruses in TZM-bl cells normalized using p24. The plasmid 
NL4-3 CMV GT was used as a positive control.  The clones that were previously characterized in the pseudovirus 
system as having high entry efficiency are colored in blue, while those having low entry efficiency are colored in 
red.  This is a representative figure of two biological repeats.  The infection was measured after 48 hours using 
luminescence.  A RLU reading of 2.5 times above background was considered a positive infection and the RLU 
reading of wells containing cells only was considered as background signal.  The NL4-3 virus was used as a positive 
control for the assay.  The NL4-3 CMV GT virus was used as a positive control for the assay. 
 
4.3.2 Viral expansion in activated PBMCs 
 
Recombinant viruses were first used to infect activated PBMCs to expand their viral titers.  The 
viruses were collected after four and seven days of infection and added to TZM-bl cells before β-
galactosidase staining method was used to monitor the number of infected cells.  Seven of the ten 
Envelope clones mediated infection after 4 days of viral expansion whereas by day 7, all of the 
T/F recombinant viruses infected TZM-bl cells.  Therefore, viruses were expanded for 7 days in 
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Table 4.1 Viral titers of the recombinant viruses after viral expansion.  The number of infectious particles was 
determined using the β-galactosidase staining method after infecting TZM-bl cells for 48 hours.  The recombinant 
viruses carrying Envelope clones with high entry efficiency in the pseudovirion assay are highlighted in grey. 
 
Recombinant virus ID Subtype  Day 4 virus titers 
(IP per μl) 
Day 7 virus titers 
(IP per μl) 
recNL4-3_390 C NI 99 
recNL4-3_89 CD 101.0 8 366.0 
recNL4-3_216 C 74.6 2 080 
recNL4-3_401 CD 67 2 200 
recNL4-3_605 AC 126.3 22 000 
recNL4-3_234 C 7.8 162.3 
recNL4-3_569 C NI 53 
recNL4-3_346 C 11.7 96 
recNL4-3_398 C 13 30 
recNL4-3_54 D NI 1.1 
*NI – no infection observed 
*IP – infectious particles 
Nomenclature: recombinant NL4-3_clone number 
 
4.3.3 Replication of recombinant viruses in PBMCs  
 
Equivalent viral titers (500 IP in 500 μl total volume) were used to infect PBMCs. Viruses were 
collected on days 4, 7, 10, and 14 after infection.   The recombinant viruses from the 10 
participants were assayed using two different PBMC donors.   
Of the ten IMCs, only four have similar relative replicative capacity in both donors (IMCs 
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level of viral production, with peak infection at 47.1 ng/ml p24 at 14 days post infection in one 
PBMC donor, while recNL4-3_398 showed the highest levels of virus production in another 
donor (with peak infection at 74.1 ng/ml p24 at day 10 post infection).  Also, the recombinant 
virus recNL4-3_54 replicated very poorly in one donor, and the replication improved by 4 to 5 
fold in the second donor.  This variability of infectivity can be attributed to differences in donor 
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                                     Days post-infection 
Figure 4.2 Replicative capacity of recombinant viruses in PBMCs from two different donors. Each bar 
represents the time the viruses were collected postinfection: days 4, 7, 10, and 14.  Viruses 390, 89, 216, 401, and 
605 represent viruses with high entry efficiency in the pseudotype virus system, and viruses 234, 569, 346, 398, and 
54 represents those with low entry efficiency.  Viral replication was measured using p24 ELISA. The plasmid 
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In order to further compare the relative replication fitness of the recombinant viruses between the 
two donors, the replicative rate was determined based on the slope of the curve from day 4 to 10 
for all the recombinant viruses and this was compared between the assays in both donors.  The 
rationale for using these time points was based on the observation that the majority of the viruses 
showed exponential growth up to day 10 post infection before plateauing or decreasing at day 14 
post-infection.  The majority of the recombinant viruses had different replicative rates between 
the two donors, and there was no similar clustering in terms of replication rate between viruses 




























Figure 4.3 Comparing differences in replication rate of the T/F viruses in two different PBMC donors.  The 
line between the points indicates the change in replication rate between the donors.  The replicate rate was measured 
as the slope of the replication curve between days 4 and 10 of infection.  The clones that were previously 
characterized in the pseudovirus system as having high entry efficiency are colored in blue, while those having low 
entry efficiency are colored in red.    
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Overall, the relative order of replication fitness in either donor did not mimic the entry efficiency 
of TZM-bl cells using the pseudovirion assay (Fig. 4.2).  
 
4.3.4 Replication of recombinant viruses in monocyte-derived macrophages 
 
Similarly, equivalent amounts of viruses (5000 IP per µl in 500 µl total volume) were used to 
infect monocyte-derived macrophages and viral titer was determined on days 4, 7, and 10.  In the 
case of recNL4-3_54 (which had the lowest number of infectious particles), the viruses was 
concentrated by ultracentrifugation before infection in macrophages.  The macrophage tropic 
virus Yu-2 was used as a positive control.  In comparison to PBMC infection, the levels of 
replication were very low in macrophages, with virus production only reaching 800 pg/ml.  
There was also extreme variation in the replicative capacity of the viruses in macrophages from 
the different donors, and the level of viral production in the macrophages fluctuated at various 
days post infection for viruses recNL4-3_54 and recNLA4-3_398.  The recombinant virus 
recNL4-3_398 was the only virus that showed consistently high replication capacity in both 
donors.  Viruses that replicated well in one of the PBMC donors (recNL4-3_54, recNL4-3_216, 
recNL4-3_401) did not replicate with the same efficiency in another donor, except for virus 
recNL4-3_54 which had enhanced replication capacity when infected in another donor. All of 
these viruses (recNL4-3_54, recNL4-3_216, recNL4-3_398 recNL4-3_401) showed higher 
levels of replication in macrophages, but this varied between donors (Fig. 4.4).  Overall, the level 
of viral replication was much lower in monocyte-derived macrophages compared to what was 
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                          Days post infection 
Figure 4.4 Replicative capacity of recombinant viruses in monocyte-derived macrophages from two different 
PBMC donors.  Viruses 390, 89, 216, 401, and 605 represent viruses with high entry efficiency in the pseudotype 
virus system, and viruses 234, 569, 346, 398, and 54 represents those with low entry efficiency.  Each bar represents 
the time post-infection when the viruses were collected: days 4, 7, and 10. Viral replication was measured using p24 
ELISA.  The macrophage tropic virus Yu-2 was used as a positive control. 
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Studies have shown that virions produced in the pseudovirus system do not always resemble the 
virus produced as an IMC (Ochsenbauer & Kappes, 2009), with one study demonstrating that 
differences in Envelope incorporation and cleavage of the envelope resulted in differences in 
infectivity and sensitivity to entry inhibitors (Provine et al., 2009).  This is partly because the 
293T cell lines, which are used to produce pseudoviruses, produce high levels of unprocessed 
gp160 (Herrera et al., 2005).  Also, certain stages of  Envelope processing and biosynthesis such 
as the addition of N- glycans to the env at a post-translational level (Willey et al., 1996) and the 
incorporation of host proteins in the progeny virus (Bastiani et al., 1997; Fortin et al., 1997; 
Goonetilleke et al., 2009a; Hioe et al., 2001; Rizzuto & Sodroski, 1997) can affect viral 
infectivity and sensitivity to neutralization between viruses (Sawyer et al.,  1994; Bastiani et al., 
1997; Willey et al., 1996; Zhang et al., 1997).  Other factors that affect the consistency in results 
between the PBMC and pseudovirion assays is the use of reagents like DEAE dextran or 
polybrene, the mode of host cell entry of the viruses (plasma membrane fusion compared to 
endocytosis) (Miyauchi et al., 2010), as well as differences in CCR5 expression (Polonis et al., 
2008).  
This study was done to compare  the infectivity  in TZM-bl cell lines of infectious chimeric 
viruses expressing the same T/F Envelopes as evaluated in the pseudovirion single cell 
replication assay, and to investigate replication of chimeric env IMCs in more biologically 
relevant conditions, including PBMCs and monocyte-derived macrophages. In order to measure 
replication capacity, the SGA-generated Envelope clones were shuttled into the NL4-3 backbone 
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the viruses, the infectivity (measured by luminescence in TZM-bl cells after 48 hours) followed 
the same trend as that was observed in the pseudovirus system: that is, viruses with higher 
infectivity generally were classified has having high pseudovirion env entry efficiency.  This 
result suggests that entry efficiency using the pseudovirion assay, at least in the most part, was a 
good surrogate marker of infectivity.  However, this observation was not upheld when PBMCs 
were used as target cells due to variation in PBMCs between donors with only 40% concordance 
in relative replication capacity between donors.   This is not surprising as viral infection can vary 
by as much as 40 - fold between healthy donors (Spira & Ho, 1995), and this variability between 
donors has also been shown to affect the neutralizing activity of certain monoclonal antibodies 
(Binley et al., 2004; Polonis et al., 2008).  This is mainly due to variation in expression levels of 
CD4 and CCR5 that exists between donors (Polonis et al., 2008). 
There were high levels of replication in CD4
+
 T lymphocytes, and low levels of replication 
observed in monocyte-derived macrophages, supporting our findings using the PSV approach, as 
well as results from recent studies (Alexander et al., 2010; Isaacman-Beck et al., 2009; Salazar-
Gonzalez et al., 2009).  The low levels of replication of transmitted viruses in macrophages 
suggest that these cells are not the critical target cells during HIV transmission (Walter et al., 
2005).   Interestingly, one virus in this study the recombinant recNL4-3 virus 54, replicated 
more efficiently in macrophages than in PBMCs, which might suggest that this virus may be 
macrophage tropic.  This virus had a subtype D envelope, was collected ~42 days post infection 
and, although it was found to use CCR5 and not CXCR4 as a co-receptor, it was resistant to both 
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In this study, we would need to expand our evaluation to many more donors, use pooled PBMCs 
from different healthy donors, or use cell lines that more closely mimic natural infection.  
Evaluation of viral replication in PBMCs is important because CD4
+
 T cells are the main targets 
for HIV infection, however the inter-assay variation between donors is a major limitation of this 
approach (Polonis et al., 2008).   Furthermore, the PBMC assays are labor intensive, expensive, 
and are not sufficient for high throughput analysis (Gauduin et al., 1996; Souza et al., 1997).   
An alternative approach is the use of suspension cells that have similar expression levels to CD4
+
 
T lymphocytes, because of their robust nature and high levels of reproducibility.  This approach 
has been used in a number of studies to measure viral replication (Alexander et al., 2010; Miura 
et al., 2009b, 2010).  Other methods that have been proposed include the incorporation of host 
cell proteins such as ICAMs, MHC class I and II molecules in 293T cells, which are proteins that 
the virus particles incorporate prior to budding from the primary cells (Cantin et al., 2005), and 
the development of hybrid assays that use pseudoviruses to infect PBMCs and primary isolates to 
infect TZM-bl cells (Polonis et al., 2008).     
In conclusion, we find that these infectious chimeric viruses carrying Envelope from the T/F 
virus preferentially replicate in T cells and not macrophages, confirming observations using the 
Affinofiles / pseudovirus approach.  Therefore, T/F viruses utilize the CCR5 coreceotor and 
require high levels of CD4 of entry. This was confirmed in our PBMC replication assay, which 
showed that T/F viruses  replicate efficiently in T cells and not macrophages irrespective of the 
infecting subtype or recombinant form. These findings support recently published studies that 
have investigated the phenotypic properties of transmitted viruses (King et al., 2013; Parrish et 
al., 2013; Ping et al., 2013). Using the recombinant NL4-3 virus system, we find that infectivity 
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important virological determinant influencing viral load in infected individuals.   However we 
were not able to validate our observation in PBMCs, and further work is required to determine if 
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Chapter 5: Summary and Conclusion 
 
High HIV-1 diversity remains one of the major obstacles in the design of an effective vaccine. 
Vaccines need to target the incoming transmitted virus and prevent it from establishing infection.  
Most studies to date have focused on understanding the properties of subtype B and C T/F 
viruses, and there is limited information on the characteristics of viruses in cohorts from East 
Africa, which may differ in circulating subtypes, prevalence of STIs, and risk behaviours.  In this 
thesis, we describe the diversity of circulating viruses in the Mbeya region of Tanzania, and 
characterize the genotypic and phenotypic properties of the T/F viral populations.  Furthermore, 
we investigate the effect of host cell entry efficiency on disease progression.  This study utilized 
samples from the HIV Superinfection Study (HISIS) Cohort, NIMR - Mbeya Medical Research 
Center, Tanzania.  
 It is known that the genital mucosa acts as a formidable barrier which usually allows only a 
single virus  to be transmitted from the donor to the recipient.  In subtype B and C cohorts in 
USA and southern/central Africa, studies have shown that this occurs in approximately 70 to 
90% of cases (Abrahams et al., 2009; Haaland et al., 2009; Keele et al., 2008).   In the HISIS 
cohort, women were infected with subtype A, C, D, or a number of unique intersubtype 
recombinants.  Seventy three percent (16/22) were infected with a single virus based on env 
sequencing (Nofemela et al., 2011),  which is very similar to the 76 % and 78 % that has been 
shown in subtype B and C cohorts respectively (Abrahams et al., 2009; Keele et al., 2008).  
These results provide further evidence of the genetic transmission bottleneck, irrespective of 










Chapter 5: Summary and Conclusion 
   131 
 
There has been a great deal of interest in the field to understand why certain viruses are selected 
over others to cross the mucosal barrier.  It is well known that these viruses predominantly utilize 
the CCR5 receptor for entry (Berger et al., 1999; Scarlatti et al., 1997; Zhu et al., 1993), and 
some studies in donor-recipient transmission pairs have shown that T/F variants have Envelope 
proteins that are neutralization sensitive relative to the donor (Derdeyn et al., 2004). These 
viruses were shown to have shorter variable loop lengths and less N-glycosylation than the 
chronically infected individuals (Chohan et al., 2005; Derdeyn et al., 2004; Sagar et al., 2006; 
Wu et al., 2006).  A number of unique signatures in transmitted viral sequences were also 
recently observed near the CD4 and CCR5 binding sites, the gp41 cytoplasmic domain, and the 
signal peptide when compared with the chronic viral sequences (Asmal et al., 2011).   Here we 
aimed to characterize the Envelope of transmitted viruses and to determine whether they share a 
common biological property.  We found major differences in entry efficiency between the 
transmitted Envelope pseudoviruses, suggesting that the mucosal barrier in the host does not 
select for viruses with the same ability to enter cells.  We found that high CD4 density on the 
target cells was critical for the entry of the transmitted viruses, with 70 % of viruses unable to 
infect cells with low levels of CD4, even at the highest levels of CCR5.  This supports recently 
published data that suggests that the transmitted viruses are not macrophage - tropic (Alexander 
et al., 2010; Ochsenbauer et al., 2012; Salazar-Gonzalez et al., 2009; King et al., 2013; Parrish et 
al., 2013; Ping et al., 2013).  As the pseudovirus system may differ from viral infection in vivo in 
terms of env processing and incorporation, thus we validated these results using chimeric IMCs 
expressing the T/F env gene.  We showed that viruses had a vast range of replicative fitness, and 
replicated efficiently in CD4
+
 T cells and very poorly in macrophages.  The preferential 
replication in CD4
+
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or recombinant form.   Therefore, despite being present at the site of infection, macrophages may 
not play a critical role during transmission.  
Our study found that entry efficiency of T/F viruses was associated with viral load at 3 and 12 
months post infection, and that this entry efficiency was related to CD4 and CCR5 binding 
affinity and, partly to Envelope incorporation and cell-cell fusion capacity.  Thus, viruses that 
have Envelope with enhanced function may influence disease progression. The role of viral 
replicative fitness in disease progression has been supported by a number of other studies (Ball et 
al., 2003; Miura et al., 2010; Quiñones-Mateu et al., 2000; Rangel et al., 2003; Travers et al., 
2005); however, in addition to our study, there has only been one other subtype B study in elite 
suppressors have showed a link between Envelope function and disease progression (Lassen et 
al., 2009). 
In conclusion, the presence of multiple subtypes circulating in a region does not seem to affect 
the transmission population bottleneck.  The characterization of the T/F viruses that established 
infection  shows that host cell entry efficiency during transmission is dependent  on both host 
and viral factors:  host factors included cell surface CD4 and CCR5 receptor levels; while viral 
factors include CD4 and CCR5 affinity, and to some extent, Envelope processing or 
incorporation and cell-cell fusion capacity. Our study showed that CD4 and CCR5 affinity of T/F 
viruses at transmission can play an important role in enhanced host cell entry, which may affect 
viral loads and subsequent disease progression.  Overall, this study has provided valuable insight 
into the viral and host factors that contribute to effective transmission by T/F viruses, and how 
these viral properties can influence the disease outcome of the infected individuals. In an intact 
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believed be the major target cells during transmission, whereby they capture  and transfer the 
virus  to the CD4
+
 T cells, This would subsequently lead to the recruitment of more CD4
+
 T cells 
to the site of infection, resulting in the propagation and dissemination of the virus to the 
neighbouring lymph nodes.  Our study together with recent publications, show that macrophages 
are not an important target cell during HIV acquisition. The preferential replication of the 
transmitted viruses in the CD4
+
 T cells suggests that these cells are the primary target cells 
during HIV transmission. Therefore, HIV crosses the mucosal barrier and establishes a small 
founder population. This population infects the target cells, which are the resting CD4
+
 T cells, 
resulting in a local expansion and subsequent migration to the genital lymph nodes where more 
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APPENDICES 







Env - AF 6202 - 6223 5’ - GAA AGA GCA GAA GAC AGT GGC - 3’ 
Env - ER 6886 – 6900 5’ - TTA GAA TCG CAT AAC CAG – 3’ 
Env - DF 7211 – 7226 5’ - AGC ACA TTG TAA CAT TAG T – 3’  
Env - AR  7783 – 7799 5’ - TGC TGC TCC CAA GAA CCC AA – 3’ 
Env - BF 6829 – 6849 5’ - TAA CAC AAG CCT TTG CCA AAG GT – 3’ 
Env – BR 6838 – 6856 5’ - AAT TTC CTA AGG TCC CCT CTG A – 3’ 
Env – MF 7644 – 7661 5’ – GCA GGA ATG AGG GAC AAT TGG – 3’ 
Env – NF 8104 – 8117 5’ - TGA CCT GGA TGC AGT GG – 3’ 
Env – NR 8342 – 8342 5’ – GGT GAG TAT CCC TGC CTA ACT CTA – 3’ 
Env - KR 8830 – 8843 5’ - CTT ATA GCA GGC CAT CC – 3’ 
Env – 1A 5953 – 5982 5’ – CAC CGG CTT AGG CAT CTC CTA TGG CAG GAA GAA – 3’ 
Env-1M 9068 – 9093 5’ – TAG CCC TTC CAG TCC CCC CTT TTC TTT TA – 3’ 
Env – E15 7101 - 7121 5’ – GTA GAA ATT AAT TGT ACA AGA CCC – 3’ 
Env -TUG 7862 - 7879 5’ – GTC TGG TAT AGT GCA ACA GCA – 3’ 
Env - ZAR 7629 - 7652 5’ – GTC CCT CAT ATC TCC TCC TCC AGG TCT – 3’ 
Env – JL74 8797 – 8817 5’ – CTG TTC TAC CCA CTT GCC ACC CAT – 3’ 
Env – JL71 8797 – 8814 5’ – TTT TGA CCA CTT GCC ACC CAT CAT – 3’ 
Env – JL89 7006 – 7025 5’ – TCC TTC TGC TAG ACT GCC ATT TA – 3’ 
Env – Z1F 6330 – 6353 5’ – TGG GTC ACA GTC TAT TAT GGG GTA CCT – 3’ 
Env – TUJ 8346 – 8362 5’ – GGT GAG TAT CCC TGC CTA AC – 3’ 
Env – TUH  7914 – 7937 5’ – GCC CCA GAC TGT GAG TTG CAA CAG ATG – 3’ 
Env–JL109 7669 – 7689 5’ – GTG AAT TAT ATA AAA TAT AAA GTA G 3’ 
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Appendix B: HIV-1 env sequences 
 
Genbank accession numbers 
The Genbank accession numbers for the 210 env sequences are HQ659584 – HQ659642, 
HQ697934 – HQ697993, HQ697994 – HQ698053, and HQ688994 – HQ689024. 
 
Appendix C: Isolation of PBMC using Ficoll-gradient centrifugation from blood 
 
1. Sterilize a pair of scissors and cut open your buffy bag. 
2. Empty the contents of the bag in one 50 ml centrifuge tube.  There is no need to do wash 
for the remnants with PBS.  
3. Make the volume up to the smallest volume dividable by 15 ml using HANKES E.g. if 
you have 40 ml of blood, make up to 60 ml (= 2 x 15 ml). 
4. Dispense the blood in aliquots of 15 ml in 50 ml centrifuge tubes.  
5. Make the volume up to 30 ml per tube using HANKES. Invert to mix. 
6. Prepare new centrifuge tubes with Ficoll, one per tube of blood.  Ficoll is light sensitive! 
7. Use 2 parts of Ficoll for 3 parts of blood.  Thus, for 30 ml of diluted blood use 20 ml of 
Ficoll per tube. 
Carefully add the 30 ml of blood in one tube of Ficoll.  Try to incline the tube so that you 
have a bigger surface of Ficoll and layer the blood gently.  Starting at an angle, gradually 
bring the tube back to a vertical position as layering progresses. 
8. Centrifuge the tubes at 1500 rpm at room temperature for 30 min.  Please note the 
following: 
- Balance the centrifuge precisely as any vibrations will disturb the separation. 
-Use slow acceleration. 
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(this will add about 15 min for deceleration).  
9. Prepare a new set of 50 ml blue-top tubes. 
10.  After centrifugation, remove the tubes slowly to avoid disturbing the separation. The 





   
11. Aspirate off most of the HANKES layer, until it is about 1-2 cm above the white cells 
layer. 
12. Carefully select the white cell layer by pipetting it up in a circular movement. 
It is ok if you take some HANKES and Ficoll.  
13. Transfer the selected fraction into a new 50 ml tube. 
14. Wash cells by topping up the volume to 50 ml with HANKES and centrifuging for 10 
min at 1500 rpm (you can put the centrifuge brake back on). 
15. Decant supernatant. 
16. Repeat wash (resuspend the cell pellet in HANKES and repeat step 14). 
17. Decant supernatant. 
18. Pool all the cells from all the 6 tubes in 1 tube with 40 ml of R-20 medium. 
19. Sample the cell suspension and make two serial 1:10 dilutions of it in trypan-blue dye.  
20. Count the cells and if you need to activate them, bring them to a final concentration of 2 
x 10
6
/ ml in RPMI complete and add PHA and IL-2: 
a. PHA add 1µl per 1  ml 
b. IL-2 add 1µl per 5  ml,  
and incubate them at 37 °C for 24 h. 
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Monocyte Isolation 
1. Make a percoll (Amersham Biosciences) gradient.  Percoll should be at room 
temperature. 
2. Make “Percoll Solution”: take 18 ml Percoll (product) and add 2 ml 1.5M NaCl. 
Make “Denser Solution”: 12 ml Percoll Solution and add 8 ml 3.8 % Citrate in PBS. 
Make “Less Dense Solution”: 8 ml Percoll Solution and add 8 ml 3.8 %Citrate in PBS. 
Make up Resuspension Medium (which consists of the following):  
- 12.6 ml RPMI (not complete) 
- 1.2 ml human serum 
- 1.2ml 3.8 % Citrate in PBS. 
3. Gently layer 16 ml of Less Dense Solution on top of 20 ml of Denser Solution. 
4. Resuspend the washed PBMC in Resuspension Medium (use all volume). 
5. Gently layer PBMC on Less Dense/Denser layered solution 
6. Spin @ 400 RCF X (i.e. ~1.5 rpm) for 30 minutes with slow acceleration and slow brake. 
7. Take off layer between less and dense gradient, which contains monocytes.  The cells at 
the bottom are lymphocytes. 
8. Wash both the monocytes and the lymphocytes with HANKES. 
 
To differentiate monocytes to macrophages (adherent cells): 
Put monocytes in Macrophage media and grow for 7 days.  Change media on Day 4. 
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Macrophage media     Total Volume 50 ml 
Macrophage SFM Medium (Gibco)    41.5 ml 
10% Human Serum (heat-inactivated 55°C, 1h)   5 ml 
5% FBS (ready heat-inactivated)     2.5 ml 
1% Glutamine       500 µl 
1% Pen-Strep       500 µl 
 
 
Appendix D: Buffers and solutions 
- Pseudovirion Western Blotting  
 
10X SDS running buffer 
30 g Trizma (250mM) 
114 g glycine (2M) 
50 ml 20% SDS 
Make up to 1 liter with ddH2O 
 
10X TBS 
24.2 g Tris (200mM) 
80 g NaCl  
Add 800 ml ddH2O. pH to 7.6 with HCl. Make up to 1 liter with ddH2O 
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 2.5 ml 1M Tris pH 6.8 
1 ml 20% SDS 
2 ml β-mercaptoethanol 
4 ml glycerol 
0.5 ml Bromophenol blue 
Store at 4ºC 
 
Block/Wash Buffer 
1 liter 1X TBS 
40 g low fat milk powder 
5 ml Tween-20 
Store at 4 ºC (Short term) 
 
Transfer Buffer 
3.03 g Trizma base 
14.4 g Glycine 
Add 1 liter ddH2O and store at room temperature 
 
Ponceau S stock solution 
2 g Ponceau S 
30 g trichloroacetic acid 
30 g 5-sulfosalicyclic acid 
Add ddH2O to 100 ml 
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10% SDS separating gel (for 2 gels) 
5 ml 30 % acrylamide mix (37:5:1) 
5.6 ml 1M Tris pH 8.8 
75 µl 20% SDS 
4.36 ml H20 
40 µl 20% ammonium persulphate 
20 µl TEMED 
5% SDS stacking gel (for 2 gels) 
0.85 ml 30 % acrylamide mix (37:5:1) 
0.625 ml 1M Tris pH 6.8 
25 µl 20% SDS 
3.5 ml H20 
10 µl 20% ammonium persulphate 
2.5 µl TEMED 
 
- Yeast gap repair  
Luria- Betani (LB) Broth 
Add to 1 liter of ddH2O the following: 
10 g tryptone 
10 g NaCl 
5 g Yeast Extract 
Adjust the pH with NaOH pellets 
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Yeast Amino Acid Dropout  Media (YEPD) 
Add 6.7 g Yeast Nitrogen Base, 6.7 g CSM-LEU to 500 ml ddH20. 
Mix and autoclave. 




Add to 1 liter ddH20 the following: 
10 g Yeast Extract 
20 g Peptone 
20 g Dextrose 
Mix and autoclave. 
 
LB Amp Plates 
Add 40 g LB Agar mix to 1 liter of ddH20. 
Adjust pH to 7 with NaOH pellets 
Mix and autoclave 
Cool to 55 °C in waterbath. 
Add 1 ml of Amp
100. 
Mix and pour into plates. 
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Yeast Amino Acid Dropout plates + FOA 
1. To 500 ml ddH20 add the following: 
20 g Agar 
6.7 g Yeast Nitrogen Base with Ammonium sulfate 
6.7 g CSM-LEU (Complete Supplement Mixture minus Leu)  
Mix and then autoclave. 
2. To 350 ml ddH20 add the following: 
20 g dextrose 
1 g 5-FOA 
Mix and check the pH of the solution. 
Allow the plates to cool at room temperature in the dark due to the possible inactivation of 5 - 
FOA by light. 
 
- Yeast plasmid rescue 
 
10 X TE Buffer 
10 ml 1M Tris-HCl 
2 ml 0.5M EDTA pH 8.0 
Add 988 ml ddH20. Store at room temperature. 
 
1 M Lithium Acetate 
Add 10.2 g Lithium Acetate to 100ml ddH20 
50 % PEG 
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Yeast Lysis Buffer 
0.1 M Tris-HCl (pH 8.0) 
50 mM EDTA 
1 % SDS 
 
3 M Sodium Acetate 
20.4 g sodium acetate 
6 ml acetic acid 
Add to 50 ml ddH20 
 
- Replication assays in PBMCs and macrophages 
 
Complete DMEM 
Remove 70 ml DMEM from the bottle, and add the following: 
50 ml FBS 
10 ml Pen Strep 
5 ml L-glutamine 
5 ml HEPES buffer 
 
Complete RPMI 
Remove 70 ml RPMI from the bottle, and add the following: 
50 ml FBS 
10 ml Pen Strep 
5 ml L-glutamine 
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- PCR and agarose gel electrophoresis 
 
50 X TAE  
To 600 ml ddH20 add the following: 
242 g Tris Base 
57.1 ml glacial acetic acid 
100 ml 0.5 EDTA (pH 8.0) 
Adjust the volume to 1 liter using ddH20 
 
0.8% agarose 
Weigh 0.4 g agarose and add to 100ml Schoot bottle. Add 50 ml 1X TAE. Boil in microwave 
and leave it to cool. 
 
- Viral titration assays 
 
Fixing solution 
To 1 liter of ddH20 add the following: 
10 ml formaldehyde (1 %) 
2 ml glutaraldehyde (0.2 %) 
 
Staining solution (for one plate) 
Add the following to a 50 ml conical tube: 
9.5 ml 1 X PBS 
200 ul 0.2 M Potassium ferrocyanide (light sensitive) 
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20 μl 2 M MgCl2 
 
0.2 M Potassium ferrocyanide 100 ml  
 
Formula weight = 422.41 g/mol 
Add 8.45 g potassium ferrocyanide to 100 ml ddH20 
0.2 M Potassium ferricyanide 100 ml 
Formula weight = 329.26 g/mol 
Add 6.59 g to 100 ml ddH20 
 
- In-house p24 ELISA 
 
Coating solution 
5 % Newborn Calf Serum (NCS): Dilute 1 ml of NCS in 19 ml PBS. 
Washing solution 
To a 1 liter bottle, add 1 liter 1 X PBS and 2 ml Tween-20 
Sample Diluent 
To 500 ml of sterile PBS, add 50 ml NCS and 2.5 ml of Triton X-100. 
Store at -20 ° 
Detection Solution 
For one plate, add 5.25 ml of TMB peroxidase substrate and 5.25 ml of TMB peroxidase 
solution. 
Stop solution 
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